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Stellingen 
De mogelijkheid om antilichamen te verkrijgen tegen instabiele antigenen 
kan bijdragen aan de ontwikkeling van betere overgangstoestandsanaloga 
en dus leiden tot katalytische antilichamen met een hogere katalytische 
efficiëntie. 
(Dit proefschrift) 
De door Thorn et al gebruikte methode om de versnellingsfactor van 
katalytische antilichamen uit te drukken leidt tot een overschatting van 
deze parameter. 
(Thorn et al, Nature 373, 228-230, 1995) 
Het bewijs voor het bestaan van enzymen die Diels-Alder reakties 
katalyseren is verre van overtuigend. 
(Laschat, Angew. Chem. 108, 313-315, 1996; Oikawa et al, ]. Chem. Soc. 
Chem. Commun. 1321-1322, 1995) 
Het door de tabaksindustrie (Philip Morris) verspreide bericht dat 
meeroken geen gevaar voor de gezondheid oplevert, berust op onderzoek 
dat uitgevoerd is naar de risico's op longkanker en mag dan ook niet 
betrokken worden op gezondheidsrisico's voor meerokers in het algemeen. 
Bovendien is dit onderzoek verricht door een door de tabaksindustrie 
gefinancierde onderneming en moet derhalve de integriteit van de 
onderzoekers in twijfel getrokken worden. 
(Smith and Phillips, British Medical Journal, 313, 929-933, 1996) 
5. Consumenten zullen met moderne biotechnologie geproduceerde 
voedingsmiddelen pas dan accepteren als deze aantoonbare voordelen, 
bijvoorbeeld wat betreft voedingswaarde, smaak of prijs, bieden boven 
"klassieke" voedingsmiddelen. 
6. Het is zinloos om een vaccin te ontwikkelen tegen cocaïne of een andere 
drug, omdat de verslaafde na deze symptoombestrijding op zoek zal gaan 
naar alternatieve geestverruimende middelen en derhalve meer gebaat zal 
zijn bij een sociale of psychologische bestrijding (oorzaakbestrijding). 
(Rocio et al, Nature 378, 727-730, 1995) 
7. Het nuttigen van "light" producten nodigt uit tot de consumptie van 
grotere hoeveelheden voedsel en leidt daardoor juist tot een hogere 
energie-opname. 
(van Dokkum, Chemisch Magazine, 439-443, 1992) 
In het huidige wetenschappelijke systeem is het beter om hypotheses te 
publiceren verspreid over meerdere artikelen en zo de citatie-index op te 
voeren, dan om in één goed artikel tot een definitieve oplossing van een 
wetenschappelijk probleem te komen. 
9. In plaats van het aanstellen van bursaal AIO's als maatregel om het 
wachtgeldprobleem uit de weg te ruimen, kunnen universiteiten beter 
overgaan tot het instellen van numeri fixi voor promovendi. 
10. Religie, atheïsme en bijgeloof zijn allen gebaseerd op geloof. 
11. Schaatsen is de enige bezigheid waarbij men met de handen op de rug tot 
grote prestaties kan komen. 
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Voorwoord 
Een promotie wordt beschouwd als de eerste werkelijke proef van 
wetenschappelijk kunnen. In mijn ogen is dat niet alles: promoveren was 
voor mij een sprong in het diepe waarbij het uiteindelijk weer bereiken 
van de oppervlakte mij heeft geleerd dat in principe alles mogelijk is als je 
maar genoeg uithoudingsvermogen hebt. Tijdens de zwemtocht naar de 
oppervlakte zwommen een aantal personen mee en velen staken 
onderweg een helpende hand toe. 
Riet, afgelopen jaren ben jij nauw bij het onderzoek betrokken geweest. 
Onze samenwerking heeft wat ups en downs gekend, maar uiteindelijk is 
het daar alleen maar beter van geworden. Jij bent iemand die kritiek zeer 
ter harte neemt en er ook daadwerkelijk wat mee doet en dat bewonder ik 
zeer. Van jouw nauwgezette manier van werken en wetenschappelijke 
instelling heb ik, als iemand met niet al teveel oog voor detail, veel 
geleerd. Arjen, jij zorgde voor prima "antilichaamtechnologische 
faciliteiten" die onontbeerlijk waren voor de totstandkoming van dit 
proefschrift. Bedankt hiervoor, en zeker ook voor de steun en het 
"meedenken" de afgelopen jaren. Colja, jij werd promotor toen het 
onderzoek al in de eindfase was gekomen. Toch wist je snel de draad op te 
pakken en al mijn epistels (zeer snel) van nuttig commentaar te voorzien, 
hetgeen, zeker in de laatste schrijfmaanden, katalyserend heeft gewerkt. 
Professor Veeger, u gaf mij de kans dit promotie-onderzoek te beginnen. 
Hiervoor wil ik u nog graag bedanken. 
Ronald Schoenmakers, Anja Boogert, Huub Kreuwel, Jan Engelbertink 
en Doeke Hoekstra, jullie hebben in het kader van afstudeervakken/stages 
allemaal een flink eind meegezwommen. Veel van jullie werk is terug te 
vinden in dit boekje. De samenwerking met jullie vond ik een van de 
leukste aspecten aan mijn promotie-onderzoek. 
An important turn in the research project was when I jumped into the 
world of phage. This was possible due to the hospitality and help of Dr. 
Greg Winter, Centre of Protein Engineering, MRC, Cambridge, UK. Greg, I 
am grateful for your hospitality and support. I also would like to thank 
Pete Jones who was my tutor in antibody phage display. Pete, thank you 
for your practical support en for many, many helpful E-mails. 
Das vierte Haupstück dieser Doctorarbeit war nie zustande gekommen 
ohne die Hilfe von Dr. Annemarie Honegger und Gastfreundschaft von 
Professor Andreas Plückthun, Universität Zürich, Schweiz. Annemarie, 
gerne möchte ich mich bei dir bedanken für die Mühe die du dich damals 
gegeben hast einer ausgezeichneter "Modelling" Arbeit zu bewerk-
stelligen. 
Ook dichter bij huis heb ik veel hulp ondervonden. Allereerst op het 
"fluorescentie-vlak". Deze letterlijk en figuurlijk schitterende techniek 
vormt een substantieel onderdeel van dit proefschrift. Ton Visser, Arie 
van Hoek, Eward Pap en Petra van den Berg, zonder jullie hulp was dit 
niet gelukt! Winfried Mulder en Masha Sergeeva, jullie waren, helaas te 
kort, deel van het katalytische antilichamenteam. Bedankt voor de fijne 
samenwerking. Michel Eppink, bedankt voor je hulp bij het visualiseren 
van de antilichaammodellen. Een goed voorbeeld hiervan is te zien in 
hoofdstuk 4. Jillert Santema, bedankt voor je hulp bij de flavinesynthese. 
Laura Ausma, bedankt voor je hulp bij vele niet-wetenschappelijke 
karweitjes op de vakgroep. 
Ook buiten de vakgroep Biochemie kwam ik graag. Vooral op het 
Laboratorium voor Monoklonale Antistoffen (LMA), waar ik een groot 
deel van mijn tijd heb doorgebracht. Alle LMA-medewerkers, bedankt 
voor de fijne samenwerking. Rikus Pomp, jou wil ik graag met name 
bedanken, vooral voor je hulp en vakmanschap die het monoklonale 
antilichaamwerk tot een succes maakten. Als ik experimenten wilde doen 
die wat minder prettig roken, maakte ik graag gebruik van de zuurkast 
van Maurice Franssen op Organische Chemie. Maurice, bedankt voor je 
gastvrijheid en ook je "synthetische" adviezen tijdens het eerste jaar van 
mijn promotie-onderzoek. Op de vakgroep Microbiologie deed ik een 
poging tot antilichaamproductie op grote schaal. Hans Scholten, bedankt 
voor je hulp bij de fermentatie-experimenten. 
Inhoudelijke bijdragen zijn vaak duidelijk genoeg. Niet zichtbaar in dit 
boekje, maar voor mij onmisbaar, waren de gesprekken, weekendjes weg, 
etentjes, schaatstochten etc. met familie en vrienden. Luc, Anne, Evert, 
René, Wendelmoet, Elles, Jan Willem, Tanja, Marc, Mirjam, Ellen, 
bedankt! Luc, de relativerende gesprekken met jou over het afronden van 
dit proefschrift hebben flink bijgedragen aan de uiteindelijke vlotte 
afronding. Papa en mama, jullie hebben mij altijd gestimuleerd "eruit te 
halen wat er in zat" en mij daarbij onvoorwaardelijk gesteund. 
Romke, jij hebt het hele traject meegezwommen en dat was voor mij 
van onschatbare betekenis. Vooral het laatste, hectische jaar heb je het 
zwaar te verduren gehad en je zult wel opgelucht ademhalen dat ik 
uiteindelijk de oppervlakte van de "promotiepool" bereikt heb. Bedankt 
voor alles. 
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Introduction 
1. Monoclonal antibodies 
1.1. Introduction to antibodies 
Basically, antibodies are proteins that have the ability to form specific, 
stable complexes with other molecules, the antigens (= a n y b o d y 
generator). Antibodies (or immunoglobulins, Igs) are produced and 
secreted by B lymphocytes. In their natural role secreted antibodies 
circulate in the blood and serve as the effectors of humoral immunity by 
searching out and neutralizing or eliminating antigens. Natural antigens 
are usually immunogenic macromolecules of protein or carbohydrate 
composition, or a combination of these. Smaller molecules such as 
peptides, steroids and other small organic molecules (called haptens) are 
only immunogenic if first covalently attached to a carrier protein. 
In principle, each B lymphocyte produces only one specific antibody. 
However, when an animal is immunized its serum is still polyclonal, i.e. 
contains many different antibody specificities. Such a heterogeneous 
population does not allow the investigation of the molecular properties of 
individual (monoclonal) clones nor is it possible to continuously produce 
unlimited amounts of antibody. In 1975 Köhler and Milstein described a 
method for the production of monoclonal antibodies (mAbs) from B 
lymphocytes immortalized by fusion to a tumour cell line [1] (further 
described in 1.4.1). This technique, the hybridoma technology, was a major 
breakthrough for which they received the Nobel prize. More recently a 
new technology has been developed, based on the production of 
antibodies in bacteria (see 1.4.2) and on the surface of filamentous 
bacteriophage, that allows the generation of monoclonal antibodies totally 
in vitro thus circumventing the need for animal immunization (see 
1.4.3). 
Nowadays antibodies and in particular monoclonal antibodies have 
been used in many biotechnological applications: as catalytic antibodies 
(see 3), in the search for specific binders (for detection and identification) 
and in therapy (for example in tumor imaging) [2,3]. 
1.2. Antibody structure 
The antibody (IgG) is a Y shaped molecule with two arms (the Fab 
fragments) joined by a flexible hinge to the stem (Fc fragment) (Fig. l.l.A). 
The tips of the arms bind to the antigen and the Fc fragment is responsible 
for triggering effector functions (like complement activation). Each 
antibody molecule consists of two identical heavy (H) chains and two 
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Fig. 1.1. A) Schematic overview of an IgG showing the domains of the heavy and light 
chains (thick black lines reflect disulfide bridges), B) Framework (FR) and complementarity 
determining regions (CDRs) of VL, C) the antigen binding domain (VH +VL) consisting of the 
CDR loops interspacing the ß-strands of this domain (drawn by Mike van Suylekom, 
Unilever Research Laboratorium). 
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identical light (L) chains. Each chain has an N-terminal variable domain 
(VL and VH on the L and H chain, respectively) that together form the 
antigen-binding site (Fv). The C terminal parts of each chain consist of 
constant (C) domains: CL for the L chain and CH1, CH2, CH3 and sometimes 
CH4for the H chain). There are two L chain classes (K and X) and five H 
chain classes (a, y, 8, e and n). The various Ig isotypes have different 
biological activities, for example IgE (that has an e heavy chain) is 
involved in triggering allergic reactions (for extensive information see 
[4]). 
2.2.2. The antigen-binding site 
The antigen-binding site of an antibody is formed by six polypeptide 
loops: three from VL (LI, L2 and L3) and three from VH (HI, H2 and H3) 
(Fig. 1.1.B). The sequence variability within the VH and VL domains is 
mainly concentrated in these hypervariable loops [5], which form the 
actual antigen-binding site. The loops are referred to as complementarity-
determining regions (CDRs). The remainder of the variable domains are 
the framework (FR) regions. These well-conserved FR regions form anti-
parallel ß-strands that together form a ß-sheet sandwich. The CDR loops 
are built on top of this ß-sheet sandwich, each loop connecting two ß-
strands. The VL and VH domains associate non-covalently to form a ß-
barrel structure, placing the CDRs close to each other at the amino-
terminal end of the VL-VH dimer (Fig. l.l.C). 
Chothia and co-workers [6] have established the concept of "canonical 
families" for five of the six CDR loops (HI, H2, L1-L3). Canonical loops are 
defined on the basis of their length and the position of canonical residues 
in the loop and in the framework. These canonical residues dictate CDR 
conformation through hydrogen bonding, packing with other CDR loops 
or part of the framework regions and torsional preferences. 
Unfortunately, not all loops are canonical and not all loops classified as 
"canonical" obey the canonical rules [7]. The H3 loop always is an 
exception because of its highly variable length, sequence and structure. 
Several residues outside the antigen-binding site have also been shown to 
be important for the conformation of CDR loops [8] and VL-VH 
interactions may have some effect on the conformation of the CDR loops 
[9]. 
There are three different types of surface topographies for antigen-
binding sites based on analysis of antibody X-ray structures: cavity, groove 
and planar. Small size antigens (haptens) give rise to a cavity topography, 
intermediate size antigens (peptides, DNA, carbohydrates) to grooves and 
the larger proteins to planar binding sites. There is no relation between a 
particular combination of CDR lengths and the type of surface topography. 
Generally, the rough topography of the binding site will be dictated by the 
backbone conformation, while the specificity for the epitope (antigenic 
derminant) will largely be determined by the side chains [10]. 
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Fig. 1.2. Simplified overview of the formation of the VH domain. L: leader sequence; V: VH 
gene segment; D: D gene segment; J: JH gene segment; C: constant domain gene segment. 
1.2.2.1. Formation of the V domains 
The immune system is capable of generating a large repertoire of 
different antibodies (~ 107 for a single mouse or ~1012 for a human being), 
from a relatively small number of gene segments (the germline 
segments). This is achieved by a combinatorial process in which the 
complete gene for the protein is produced through recombination of a 
number of gene segments, each of which is drawn from a pool of 
moderate size. The VH domain is assembled by the recombination of three 
gene segments: VH, D and JH(see Figure 1.2). This region includes the first 
and the second CDR of the H chain. The third loop is formed by all the 
three segments: the end of VH, D and the beginning of JH- The VL domains 
are formed by a combination of two gene segments VL and JL. As in the VH 
domain, the VL segment codes for the first two CDRs and the third CDR is 
formed by the end of VL and the beginning of JL. The enormous diversity 
generated this way is further augmented by a phenomenon known as 
junctional flexibility. This is based on the imprecise joining of sequences 
and leads to many non-productive rearrangements, but it also generates 
several productive combinations, thereby increasing antibody diversity 
[4,11]. 
The primary antibodies produced by gene recombination are capable of 
recognizing all antigens with at least moderate affinity. Cells producing 
these antibodies are selected by encounter and binding of antigen, and 
they are triggered to differentiate to short-lived plasma cells that secrete 
antibody and to long-lived memory cells that persist in lymph nodes, 
spleen, and bone marrow. The V genes coding for the selected antibodies 
displayed on memory cells are subject to somatic hypermutation, leading 
to antibodies of improved binding affinity after further selection with 
antigen. Thus, repeated immunization leads to "affinity maturation" of 
the response. 
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1.2.2.2. Modelling of the antigen-binding site 
To understand the molecular basis of antibody specifity, high 
resolution X-ray crystallographic or NMR structures of free and antigen-
bound antibody are required. If such a structure is not available, advantage 
can be taken of the highly conserved and well-studied structures of 
antibody V domains in order to generate models of antibodies. Antibody 
modelling has attracted increased interest over the past few years, owing 
to an explosion in the number of published antibody sequences [12], a 
gradual increase in availability of well-resolved crystal structures [13] and 
the availability of fast work stations. 
The approaches taken to modelling of the antigen-binding site can be 
divided in two groups: knowledge based and ab initio. In the first 
approach antibody crystal structures from which CDRs are selected on the 
basis of length and/or sequence are used as templates to construct models. 
Advantages of knowledge-based approaches are that starting structures are 
known to exist in nature and that less computer time is needed compared 
to ab initio methods. The main limitation of this approach is the number 
of available antibody structures. The second approach in antibody 
modelling is based on ab initio methods that generate all possible loops by 
conformational search methods (see for example [14]). The drawback of 
this approach is that the number of loop conformations increases in size 
exponentially as the length of the loop increases. Therefore this method is 
only suitable for short loops. Ab initio methods fail to make use of the 
valuable information available in the structural database [13] and, 
consequently, are expensive in computer time. 
To date, the knowledge-based and ab initio approaches, when used 
alone, have had only limited success [15]; they are not routinely able to 
construct all six CDRs with a high level of accuracy. Martin and co-
workers [16] have combined the two approaches in a computer program 
(AbM [17]) that overcomes the limited size of the knowledge base by using 
conformational search methods but does not ignore the information 
available in the structural data base. This program is a "black box" 
program (i.e. sequences of heavy and light chains have to be imported and 
then the program generates the antibody model) and works fairly well 
when CDR HI, H2, L1-L3 belong to canonical families and H3 is short [15]. 
Interactive modelling programs, based on a combination of a knowledge 
based and an ab initio approach, are also available (for example [18]). These 
programs allow the user more freedom but also require more experience 
and knowledge of the user. When constructing an antibody-antigen 
model, possible conformational differences in the free and bound forms of 
the antibody must be considered as well as the flexibility of the antigen. In 
general haptens are more rigid than peptides or proteins and therefore 
easier to deal with. 
The validity of antibody models must be confirmed by binding (e.g. 
ELISA, fluorescence or surface plasmon resonance [19]) or mutagenesis 
studies. Reliable models can provide valuable information for 
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betterunderstanding antibody-antigen interactions, antibody catalysis [20], 
to improve binding by mutagenesis, to "humanize" antibodies for therapy 
[21] and even for the complete de novo design of new antibodies [10,22]. 
1.3. Antibody-antigen interactions 
Perhaps the most important function of antibody molecules is to 
specifically combine with the corresponding antigen to form an antibody-
antigen complex. The attractive and repulsive forces involved in 
antibody-antigen interactions are the same as for other non-covalent 
protein-ligand interactions: on the one hand hydrogen bonds, Van der 
Waals interact ions, electrostatic interactions and hydrophobic 
interactions, and on the other hand steric repulsion forces caused by a 
non-optimal complementarity. The better the complementarity between 
antibody and antigen, the lower the repulsive forces. Antibody affinity is 
the summation of these attractive and repulsive forces. Affinity is a 
thermodynamic measurement of the strength of the non-covalent 
interaction between an antigenic determinant and the homologous 
antibody binding site and can be described as the dissociation constant K 
(ranging from 105 to 10~10 M'for antibodies) or as the standard free energy 
change AG0 ' for binding: 
K = kdiss /kass = [Ab-Ag]/[Ab].[Ag] 
AG0' = -RT InK 
The term affinity indicates the strength of an interaction between one 
site of the antibody and one site of the antigen. However, full size 
antibodies have more binding sites, that can each complex to an antigen. 
In case the antigen is multivalent or linked to a surface, large networks 
are formed. In contrast to affinity, avidity is an operational term 
expressing the total strength of an antibody-antigen interaction and 
depends, therefore, not only on affinity but also on multivalency of 
antibody and antigen and other non-specific factors. Basically, the 
measurement of antibody affinity depends upon the determination of free 
and antibody-bound antigen or free and antigen-bound antibody at 
equilibrium. Such determinations are usually performed over a range of 
antibody or antigen concentrations. Affinities can be determined using 
various techniques such as Enzyme-Linked Immunosorbent Assay 
(ELISA) [23], fluorescence spectroscopy [24-26] or surface plasmon 
resonance [27]. 
1.3.1. Molecular basis of antibody-antigen interactions 
The H chain seems to play a dominant role in antigen-binding. 
However, there are also examples of antibodies in which the L chain is 
predominantly involved in antigen-binding. The minimum number of 
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CDRs used in binding, even the smallest antigens, is four. Conversely, 
antibodies binding larger antigens do not necessarily use all six CDRs. An 
analysis of known structures shows that L3 and H3 are always used and 
play a dominant role in ligand binding, the contact with other CDRs and 
with the opposite domain [28,29]. There is a surprising lack of interaction 
between L2 and smaller antigens or haptens (for overview see [29]). 
Despite the "lock and key" appearance of antigen-antibody complexes, 
both antibodies and ligands are dynamic entities that undergo structural 
fluctuations [30]. Conformational adjustments may even be required for 
binding. "Induced fit" can be achieved by side chain shifts or rotations, 
CDR conformational changes and even VH and VL domain shifts. Where 
significant conformational changes occur in the antibody, H3 has always 
been involved so far [30]. 
New insights reveal that solvent molecules also help to mediate 
antibody-antigen interactions by forming hydrogen bonds, increasing the 
packing density and contributing to charge complementarity [31]. So most 
of the ordered water molecules in the free antigen-binding site are 
retained upon complex formation (instead of transfer to bulk solvent). 
Recruitment of additional water molecules has also been observed. Both 
effects restrict the entropie contribution to binding energy but this is 
compensated by a more favorable enthalpy. The location of water 
molecules becomes more certain with the higher resolution of the X-ray 
structures nowadays. 
1.4. Antibody technology 
1.4.1. Hybridoma technology 
In 1975 a method was described for making cell lines that secrete a 
single species of antibody (monoclonal antibody) with the desired 
specificity to antigen [1]. This technology is based on the fusion of spleen 
cells from an immunized animal with myeloma cells resulting in hybrid 
myeloma or hybridoma cells. Myeloma cells are tumour cells that have 
the ability to grow in vitro and were altered in such a way that they do not 
express antibodies themselves. Thus, the hybridoma cell obtains its 
immortality from the myeloma cell and capacity to produce antibodies 
from the spleen cell. 
The first step in hybridoma technology is animal (usually mouse) 
immunization. Immunization is essential to derive hybridomas secreting 
high-affinity antibodies. Upon the first immunization step antibodies of 
low affinity are produced (usually IgMs). This involves proliferation of 
cells drawn from the repertoire already available at the time of 
immunization (107-108 clones in a mouse). After a second immunization 
high affinity antibodies (mainly IgGs) are formed, due to hypermutation 
of the genes used in the first stage. The actual immunization protocol 
depends on the nature of the antigen and the mouse strain used. 
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Fig. 1.3. Overview of hybridoma technology (see text for details). 
Spleen cells of the hyperimmunized mouse are then fused with 
myeloma cells using polyethylene glycol or electrofusion. Unfused spleen 
cells die because they lack the ability to grow in vitro. Unfused myeloma 
cells are eliminated by blocking the synthesis of the essential metabolite 
guanosine monophosphate (GMP) using azaserine or aminopterin. In 
normal cells this problem can be circumvented in an alternative pathway 
via the enzyme hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) that converts hypoxanthine in GMP. Myeloma cells lack HGPRT 
and will therefore die in a selective medium. Spleen cells, however, 
possess this enzyme and provide it to the hybridoma cell that can thus 
survive in this selective medium (Fig. 1.3). 
After fusion, clones are screened for antigen-binding by assays such as 
the Enzyme-Linked Immunosorbent Assay (ELISA). Positive clones are 
produced as stable monoclonal clones by cloning them under limiting 
dilution conditions. 
Hybridoma technology has led to a wealth of murine monoclonal 
antibodies with predefined specificity. However, the technique depends 
on animal immunization followed by culturing mammalian cells which 
is both time-consuming and expensive. Moreover, hybridoma cells are 
not easily accessible for genetic engineering which precludes the use of 
mutagenesis experiments in order to improve or study binding properties 
or catalytic activity of antibodies. Furthermore, it is difficult to produce 
human monoclonal antibodies (needed for therapy and in vivo 
diagnostics), partly for ethical reasons. 
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1.4.2. Antibody expression in E.coli 
Due to the developments in recombinant DNA technology it is now 
possible to produce antibodies in E.coli. Production in E.coli has several 
attractive features: genetic manipulations are quite simple and well-
established, growth is rapid, fermentation is relatively simple and the 
transformation efficiency of E. coli is probably better than of any other 
micro-organism. However, it is not possible to express full size antibodies 
in E.coli because bacteria are not capable of glycosylating the Fc part of the 
antibody. Glycosylation seems to contribute to stability and is essential for 
biological effector functions [32]. As the antigen-binding parts of an 
antibody are usually not glycosylated, these fragments can be produced in 
E.coli in their natural form and can be used for purposes for which no 
effector function is needed: as catalytic antibodies, for studying antibody-
antigen interactions or fusion with enzymes or toxins. 
1.4.2.1. Choice of fragment 
The smallest antibody fragment containing the complete antigen-
binding site is the Fv fragment composed of the variable domains VL and 
VH (Fig. 1.4). The relative affinity of VL and VH for each other depends on 
the particular sequence of the antibody [33]; the domains may dissociate in 
one antibody, while others do not have this problem. The reversible 
dissociation of the Fv fragment can be counteracted in several ways: 
chemical cross-linking [34], engineering of disulfide bonds into the 
fragment [34,35] or covalently linking VL and VH by a genetically encoded 
peptide linker (resulting in a single chain Fv fragment, scFv) [36]. The first 
method requires obtaining the Fv fragment in the first place and is 
therefore not generally applicable. The second method, comprising genetic 
engineering of disulfide bonds, overcomes this problem but suffers the 
drawback that the positions to engineer these bonds are not universal for 
all antibodies. The latter method is the most popular due to its universal 
applicability. A variety of peptide linkers has been tested [37] and the most 
frequently used one has the sequence (Gly4Ser)3 [38]. NMR evidence 
suggests that this linker is a flexible entity, which does not change the 
structure of the variable domains [39]. Closest to the naturally occurring 
antibodies is the Fab fragment consisting of a covalently associated light 
chain and a part of the heavy chain (Fig. 1.4). The constant domains 
substantially contribute to the interactions between the heavy and the 
light chain and thus increase the stability. 
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1.4.2.2. Folding, 
E.coli 
secretion and purification of antibody fragments from 
At first antibodies could only be produced in E.coli as cytoplasmic 
inclusion bodies [40,41]; refolding experiments led only to a small 
percentage of correctly folded antibody. Moreover, experiments with a 
number of fragments have shown that the refolding procedure has to be 
adapted to the particular fragment under study [37]. Additionally, correctly 
folded molecules must be separated from soluble, but incorrectly folded 
material. 
In 1988 two publications appeared at the same time describing the 
functional expression of antibody fragments [42,43]. The expression system 
described was the result of attempts to reproduce in E.coli the folding and 
assembly pathway of antibodies in eukaryotic cells. In the eukaryotic 
plasma cell, the two chains of an antibody are separately transported from 
the cytoplasm to the lumen of the endoplasmic reticulum (ER). This 
transport requires an amino-terminal signal sequence, which is cleaved 
off after or during the translocation event by a signal peptidase to produce 
the mature protein. In the lumen of the ER protein folding, formation of 
disulfide bonds and association of individual chains to form the 
functional antibody take place. These steps must be mimicked in the 
bacterial cell. The crucial hypothesis in the design of the secretory system 
for antibody fragments was that protein transport from the reducing 
environment of the cytoplasm to the oxidizing periplasm is functionally 
equivalent to the transport of a protein to the lumen of the ER of the 
eukaryotic cell. This was achieved by equipping heavy and light chains, 
obtained from hybridoma cells, with signal sequences that direct both 
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chains to the periplasm. In the periplasm both chains were correctly 
folded and assembled and the intramolecular disulfide bonds, that 
appeared to be crucial for the antibody stability [35], were formed. This 
approach led to the formation of functional antibody fragments with the 
same affinity constants as the whole antibody or its proteolytic Fab 
fragments. 
Usually, for purification the antibody fragment is selectively liberated 
from the periplasm as a functional and soluble protein by EDTA 
treatment combined with osmotic shock [44] (subcellular fractions termed 
"cytoplasmic" contain membrane-associated periplasmic antibody 
material that is pelleted together with the spheroblasts [45]). However, 
under conditions of prolonged high level expression and at elevated 
expression temperature, the outer membrane of E.coli becomes permeable 
[46] and the fragment can be isolated from the culture medium [44]. 
Secretion into the medium may be useful for analytical work but for large 
scale preparations it is generally considered more practical to prepare the 
protein from the whole cell or the periplasmic fraction. Purification of the 
recombinant antibody fragments is facilitated by the incorporation of 
• genetically encoded carboxyl-terminal peptide tags, for example a 
hexahistidine tag for Immobilized Metal Chelate Chromatography (IMAC) 
[47]. Nowadays, several hundreds of milligrams of antibody can be 
produced using high-cell density fermentation of E.coli [48,49] but this is 
not common practice in most laboratories since sophisticated fermentor 
systems and clones producing reasonable amounts of antibody fragments 
are required 
Despite this success, it appears that only part of the secreted antibody 
folds correctly in the periplasm and the remainder of the secreted protein 
is deposited as insoluble material [50]. The yield of the folding process 
depends primarily on the primary sequence [51], but also on temperature 
and growth physiology [51] and the type of fragment used [52]. It appears 
that aggregation, which is a side reaction of folding, limits the folding 
yield [51]. Empirically the simplest method to improve the folding yield is 
to lower the growth temperature of the cells to about room temperature 
[52,53]. The distribution of folding intermediates between pathways of 
folding and aggregation is probably more favourable at lower temperature 
[53]. However, the most effective way to improve folding may be to 
change the primary sequence of the antibody. Knappik and Plückthun 
introduced mutations in turns of the antibody loops which reduce the 
formation of aggregates and diminished the lysis of the bacterial cells [51]. 
However, the mechanism of how these mutations accomplish their 
effects is not yet known and therefore this approach must be optimized for 
each particular antibody sequence. 
In contrast to natural occurring antibodies, Fab, Fv and scFv fragments 
lack multivalency, which is a very effective means of increasing the 
functional affinity (avidity) to a surface or a polymeric antigen. This 
problem can be solved by further protein-engineering of the recombinant 
antibody fragments: either by using a linker that is too short to allow 
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pairing between the two domains on the same chain, forcing the domains 
to pair with the complementary domains of another chain resulting in a 
bivalent "diabody" [54] or by linking scFv fragments by small amphiphatic 
helices resulting in bivalent [55] and tetravalent [56] miniantibodies. The 
production of whole functional antibodies in E.coli remains impossible. 
However, if applications are envisaged, where glycosylation would be 
vital, the stepwise engineering of the binding site may still be performed 
in E.coli, and the final version of the antibody may then be expressed in 
mammalian cells [57], yeast [58], insect cells [59,60], fungi or plants 
("plantibodies"), although glycosylation is different in each system [61]. 
2.4.3. Antibody phage display 
Despite the fact that expression of antibodies in E.coli has overcome the 
need for culturing hybridoma cells and genetic manipulation of 
antibodies is much facilitated, animals still "invent" the antibody 
molecules. Antibody expression in E.coli proved to be the key step to 
circumvent even this. Recombinant DNA technology has enabled the 
immortalization of antibody heavy and light chain V-genes, instead of 
immortalizing B-cells, for production of monoclonal antibodies. These 
genes can be displayed on the surface of filamentous bacteriophage 
allowing mimicking of immune selection [62] and nowadays antibodies 
can be selected totally in vitro . 
1.4.3.1. Principles of phage display 
In the first instance, filamentous phage have been used for the display 
of peptides [63]. Nowadays antibody fragments can be displayed on phage 
[62] as well as as functional enzymes and other proteins such as receptors, 
protease inhibitors and DNA binding proteins (for review see [64]). The 
single-stranded DNA genome of non-lytic filamentous bacteriophage 
(such as M13 or fd) is coated with approximately 2700 copies of the major 
coat protein, pVIII, forming a thin flexible cylinder around the enclosed 
genome. Three to five copies of the minor coat protein, pill, are located at 
the tip of the phage particle (for a extensive description see [65]) (Fig. 
1.5.A). Although both pill and pVIII can be used for display, both leaving 
the phage infective, fusions to pill are preferred for antibody display to 
prevent strong avidity effects [66]. 
The pill protein has two domains. The amino-terminal domain, which 
extends from the phage particle as a knob-like structure, binds to the 
bacterial F-pilus to infect male E.coli bacteria. The carboxy-terminal 
domain anchors pill into the phage coat. Antibody fragments are fused to 
the amino-terminus of pill (Fig. 1.5.B), which is, during phage assembly, 
located in the periplasm of their bacterial cell where the antibody 
fragments can fold and assemble. Bacteria infected by phage become 
resistant to further infection and therefore phage, like the B cell, each 
carry only a single antibody species. 
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Fig. 1.5 Wild type (A) and antibody (Fv fragment) displaying phage (B). 
To achieve display of antibody fragments, V-genes are genetically fused 
to gene III (coding for protein III) either in a phage vector or in a 
phagemid vector. Phagemids are plasmid vectors, harbour ing 
bacteriophage gene III, that can be packaged into phage particles, but 
require the use of helper phage [67]. Phage vectors should lead to three to 
five copies of the antibody fragments on each phage (assuming no 
proteolysis), but with phagemids the pill coat protein of the helper phage 
competes for incorporation into the phage particle, resulting in an average 
display of less than a single fusion protein per particle [66]. When an 
amber stop codon is introduced between the antibody gene and gene III it 
is possible to mimic the switch from surface display to secretion of soluble 
antibody from plasma cells. When phage are grown in a supE suppressor 
strain of E.coli, this amber codon is read as a glutamine and the antibody is 
displayed on top off the phage. In non-suppressor strains the amber codon 
is read as a stop codon and soluble protein is secreted into the bacterial 
periplasm [68]. 
1.4.3.2. Antibody phage display libraries 
Antibody genes can be amplified from hybridoma or B cells using the 
polymerase chain reaction (PCR). The key step towards expression of 
whole repertoires of V-genes (libraries) came from the use of "universal" 
PCR primers, suitable for amplifying a range of heavy and light chain V-
genes, and the cloning of amplified DNA directly into expression vectors 
[69]. The resulting libraries are combinatorial, i.e. amplified heavy and 
light chain V genes are randomly recombined irrespective of their pairing 
in vivo . Libraries can be either biased or naive (Fig. 1.6). In biased libraries 
the repertoires of VH and VL genes are amplified from the spleen mRNA 
of hyper-immunized mice [70]. Immunization enriches the mRNA for VH 
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Fig. 1.6. Antibody production in vitro and in vivo and an overview of the libraries that can be 
generated in vitro. Mutations, introduced by affinity maturation, are represented as dots. 
and VL genes encoding binding activities [71,72]. Libraries from 
immunized sources provide high affinity antibodies (Kd < 109 M) to the 
immunogen without the need to construct hybridomas. However, animal 
immunization is required and this results in a different library for each 
antigen [70,73]. 
It is possible to by-pass immunization using naive repertoires (i.e. V-
genes derived from a non-immunized source). However, the probability 
of isolating a clone from such a repertoire is dependent on the size and 
diversity of the library: larger libraries should lead to the isolation of 
antibodies against more epitopes and also to antibodies exhibiting higher 
affinities [74]. The first naive libraries (repertoire size ± 107), derived from 
rearranged V-genes (see 1.2.2.) and therefore called natural libraries (Fig. 
1.6), produced only a few different specificities of moderate affinity [75,76]. 
The diversity of the V-genes can be extended by a synthetic approach 
using unrearranged V-gene segments from stem cells, encoding the first 
two CDRs, as building blocks; from human individuals repertoires of 51 
human VH segments [77], 40 VK [78] and 30 Vx [79] gene segments have 
been cloned. In vivo the third CDR is generated from the recombination 
of these segments with the D and J segments for the heavy chain and with 
J segments for the light chains, in this way multiplying the diversity. In 
vitro this process is mimicked by creating a synthetic CDR3 using PCR 
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with diverse oligonucleotide primers (Fig. 1.6). These synthetic naive 
libraries (repertoire size of ~108 clones) have yielded antibodies of different 
specificity and moderate affinities (105-107 M) [80,81]. 
However, the limiting factor in the generation of large phage library is 
the transfection efficiency of bacteria; in practice this limits the library size 
to 107-109 clones [66], although by several hundreds of transformations a 
very large library (1.4 x 1010) that led to antibodies with sub-nanomolar 
affinities has been obtained [82]. These transformations could be 
circumvented by a "combinatorial infection" approach [83]. Bacteria 
harbouring a "donor" heavy chain repertoire on a plasmid are infected 
with an acceptor light chain repertoire on phage. The two chains were 
combined on the same (phage) replicon within the bacterium by Cre 
catalysed recombination at so called loxP sites [83]. This process generates a 
large number of heavy and light chain combinations, potentially as large 
as the number of bacteria that have been infected by phage (phage 
infection is extremely effective and most E.coli cells in an exponentially 
growing culture can be infected). Griffiths et al [84] have constructed a 
library of 6.5xl010 clones that has yielded antibodies with affinities in the 
nanomolar range. Thus using naive libraries both hybridoma technology 
and immunization could be by-passed. Moreover, the same library can be 
used to select phage antibodies against a wide range of different antigens. 
1.4.3.3. Selection of phage antibodies from libraries 
Phage encoding the displayed antibody fragment can be affinity selected 
from libraries for binding to a particular antigen by passing the phage 
antibodies over antigen bound to a solid surface ("panning"). Several 
formats have been used for the affinity selection of the phage, such as 
antigen on a column matrix [62,70], antigen-coated plastic tubes or dishes 
[75], biotinylated antigen in solution followed by capture on streptavidin-
coated beads [85] and whole cells [86]. Phage that display antibody 
fragments specific for the antigen are retained on the surface. Non-binders 
are removed by washing and bound phage antibodies are washed and 
eluted by soluble antigen (specific) [70] or acid [73] or alkali [75] (aspecific) 
and used to reinfect E.coli (Fig. 1.7). The selected phage are grown after 
each round of panning and selected again so that rare phage can be 
isolated after several rounds of panning [62]. Since the antibody fragments 
on top of the phage are linked to the genes encoding them, the panning 
procedure, that selects for antigen-binding phage, coselects for its DNA 
sequence simultaneously. 
The power of selection is limited mainly by the efficiency at each round 
of selection: it seems that only a small fraction of the phage (<1%) can be 
recovered [87,88]. Thus to guarantee selection of at least one copy of a 
binding clone, it is necessary to have many copies present. By carefully 
optimizing selection, specific binding phage can be enriched 50-fold per 
round of selection leading to a 107-fold enrichment after four rounds of 
selection. 
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Selection efficiency can be further improved by linking antigen-
recognition and phage replication [89,90]. Antibody libraries have been 
displayed on the surface of engineered, non-infectious phage with gene III 
deletions (see 1.4.3.1.). Antigens are then expressed as fusion proteins with 
gene III. Consequently, antigen-specific phage become infectious by 
binding to the gene III fusion product. Using this method one specific 
phage among 1011 non-specific particles could be recovered [89]. However, 
use of this system is restricted to protein and peptide antigens that can be 
genetically fused to gene III. 
The successful expression of antibodies in E.coli [42,43], the use of 
universal PCR primers to clone repertoires of heavy and light chain V-
genes [69] and the display of antibody fragments on filamentous phage [62] 
has led to the isolation of highly specific antibodies. Among these are 
human antibodies (even against self-antigens) [76] and antibodies against 
unstable haptens (see chapter 3 [26]) that are generated by-passing 
hybridoma technology and even immunization, from naive antibody 
phage display libraries. The construction of very large repertoires even 
allows the isolation of high-affinity antibodies [84]. As in the immune 
system, selected antibodies from a primary library can be mutated and 
those with improved affinities isolated [85,91]. 
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2. Flavins and flavoproteins 
Flavin (7,8-dimethylbenzo[g]-pteridine-2 /4(3H,10H)-dione) is widely 
distributed in nature, free and bound to proteins. Riboflavin (Fig. 2.1), 
better known as vitamin B2, is the most abundant natural flavin 
compound. Whereas lower organisms produce flavin biosynthetically, 
mammals have lost this capacity and have to take up flavin via their 
food. A large number of flavoproteins isolated from various biological 
sources have been characterized to date. These flavoproteins can be 
distinguished in flavoenzymes (2.2), which catalyze a wide variety of 
redox reactions, and flavin-binding proteins, which play a role in flavin 
storage and transport (2.3). 
2.1. The flavin molecule 
The most interesting feature of the versatile flavin molecule consists of 
its redox properties, which can be modulated by the (protein) 
environment. The redox active part of the flavin is the isoalloxazine ring 
(the three-membered ring system, Fig. 1.8) which can exist in oxidized 
flavoquinone, one-electron reduced flavosemiquinone and two-electron 
reduced flavo-l,5-dihydroquinone states. The three redox states can each 
exist as cationic, anionic or neutral species; protonat ion and 
deprotonation can occur at more than one atomic site . In this thesis 
emphasis has been laid on oxidized flavin and 1,5-dihydroflavin and 
therefore the properties of these molecules will be discussed further. 
Oxidized and 1,5-dihydroflavin differ substantially in their charge 
distribution and conformation. Both oxidized and reduced flavin are 
flexible molecules. Oxidized flavin is most stable in the planar 
conformation but nevertheless highly flexible around the N(5)-N(10) axis 
[92]. N(10) is generally slightly out of plane, but hydrogen bonding may 
cause N(10) to become coplanar [92]. The pyrimidine like nucleus (ring C 
in Fig. 1.8) is by far the most polar portion of the isoalloxazine moiety. The 
most positive ring atoms are the carbonyl carbons. N(l) and N(3) are the 
most negative ring atoms, whereas N(5) and N(10) are nearly neutral. The 
benzene like ring (ring A in Fig. 1.8) shows typical aromatic charge values 
[93]. 
Reduced 1,5-dihydroflavin is bent along the N(10)-N(5) axis with typical 
fold angles around 155°, depending on the axial N(10) substituent [92]. 
N(5) substituents vary in orientation and no obvious pattern is known 
[92], Upon reduction C(4a), N(5) and N(10) become more negative and 
N(l) less negative. In contrast to these shifts of charges, the partial charges 
in the 0=C-NH-C=0 moiety remain virtually unchanged, suggesting 
electronic isolation from the rest of the conjugated system. Changes in 
partial charge extend even into ring A [94]. 
The pKa of the N(l) of reduced flavin is 6.7, implying that this nitrogen 
often is deprotonated. The deprotonated N(l) bears the largest share of the 
negative charge adopted but the carbonyl oxygens in ring C also become 
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Fig. 1.8. Structures of riboflavin, FMN and FAD, both in the oxidized quinone (A) and the 
two electron reduced 1,5-dihydroquinone form (B). Riboflavin, R = ribityl; FMN, R = 5'-
monophosphate-ribityl; FAD, R = 5'-monophosphate-ribityl-adenine. 
more negative. Partial charges on the other atoms remain unchanged but, 
surprisingly, the C(7) and C(8) methyl groups adopt part of the negative 
charge [93]. The geometry of deprotonated flavin is not greatly different 
from the neutral molecule [92] although earlier it was proposed that 
anionic reduced flavin is more bent than its neutral form [95]. 
A prominent feature of the flavin molecule is its spectral properties. 
The yellow oxidized flavin has two characteristic absorption maxima at 
445 nm and 367 nm, that disappear upon two electron reduction. Flavins 
fluoresce in the green spectral region where the position and intensity of 
the emission maximum is dependent on the molecular environment. For 
example, the fluorescence of protein-bound flavin can be rather weak 
which sometimes can be ascribed to energy transfer to electron-rich 
aromatic amino acids. The advantage of this green fluorescence is that the 
signal can be distinguished from the characteristic protein emission signal 
in the UV spectral region. 
Oxidized flavin can be studied with both steady-state and time-resolved 
fluorescence spectroscopy. Reduced flavin, on the other hand, is only very 
weakly fluorescent, due to its low visible light absorption and its 
preference for the bent conformation that gives rise to a weak picosecond 
fluorescence [96]. Reduced flavin can only be studied with time-resolved 
fluorescence due to the sensitivity of this technique [25,96,97] or at very 
low temperature in rigid glasses [98]. Time-resolved polarized 
fluorescence also gives information about the flexibility of the flavin 
binding as compared to overall or segmental motions of the protein. 
2.2. Flavoproteins 
2.2.1. Flavoenzymes 
In their function as cofactor flavins mediate a variety of chemical 
reactions including dehydrogenation, electron transfer, activation of 
molecular oxygen and photochemical reactions. For example, flavin is the 
photoactive chromophore in DNA repair enzymes (DNA photolyases). 
Theoretically, flavoproteins can make use of all three redox states during 
catalysis. But it turns out that they selectively use only certain redox states, 
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depending on their biological function. For example, in case of the DNA 
photolyases, two electron reduced FAD is the active form of the flavin 
cofactor; pyrimidine dimers are split (i.e. repaired) via donation of an 
electron from a photo-excited reduced flavin to the dimer, thereby 
forming a pyrimidine dimer anion that collapses to two monomeric 
pyrimidines [99]. 
Flavoenzymes do not use the naturally occurring riboflavin as a 
cofactor but use FMN or FAD instead (Fig. 1.8); apoflavoproteins generally 
exhibit a great specificity for one particular flavocoenzyme. Furthermore, 
a number of chemically modified flavins have been found in 
flavoproteins such as 8-hydroxy- and 6-hydroxy-FAD [95]. Flavin cofactors 
are in general noncovalently bound to the apoflavoproteins (in the range 
from mM to almost pM) although in a number of flavoproteins 
covalently bound flavins occur. 
Flavoenzymes can be grouped into a small number of classes based on 
properties as the type of reaction catalyzed, the ability to use molecular 
oxygen as electron acceptor and the nature of auxiliary redox centres. The 
first itemization is in two groups: simple flavoenzymes, i.e. flavoenzymes 
containing no other prosthetic group than flavin, and flavoenzymes that, 
apart from flavin, use auxiliary redox centres [100]. The simple 
flavoenzymes can be subdivided in three major classes: oxidases, electron 
transferases and monooxygenases [100]. These subclasses will be shortly 
discussed since they will be referred to in this thesis. 
Oxidases (such as D-amino acid oxidase, glucose oxidase, lactate oxidase) 
accept electrons from substrates and use oxygen as terminal electron 
acceptor, forming hydrogen peroxide and oxidized substrate. Oxidases 
shuttle between the flavoquinone and hydroquinone; flavohydroquinone 
is very reactive towards oxygen but reacts slowly with one-electron 
acceptors. In most oxidases the dihydroflavin is held in a more planar 
conformation than free in solution which probably makes them more 
reactive towards oxygen. 
The electron transferases, e.g. flavodoxin, are all involved in one-
electron transfers. Characteristic of this class is the slow reaction with 
oxygen, a process in which superoxide (02~) and flavosemiquinone are 
formed. Flavodoxins can mediate electron transfer between other 
substrates or proteins, for example the strictly two electron-reacting 
nicotinamide nucleotides or the strictly one electron-reacting heme 
proteins. 
Monooxygenases, like p-hydroxybenzoate hydroxylase and bacterial 
luciferase, catalyze insertion of an oxygen atom into a substrate 
(oxygenation). To achieve this, the enzyme is reduced by NADH or 
NADPH and, upon reaction with oxygen, a C(4a) hydroperoxide radical is 
formed. This hydroperoxide transfers an oxygen atom to the substrate, 
resulting in a C(4a)-hydroxyflavin, which upon dehydration returns to 
oxidized flavin. In absence of substrate, the hydroperoxide converts to 
oxidized flavin and H 20 2 (the monooxygenase than acts like an oxidase). 
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2.2.2. Non-catalytic flavin-binding proteins 
In addition to flavoenzymes there are also a number of other flavin-
binding proteins, which are not catalytically active. The most well-known 
examples are egg white riboflavin binding protein and yolk riboflavin 
binding protein that play a role in the development of oocytes [101]. 
However, in 1985 it was shown that in man immunoglobulins (Igs) are 
the proteins most responsible for binding riboflavin (vitamin B2) [102]. 
These Igs are thought to be responsible for the individual variations of the 
riboflavin levels in healthy men as well as of the abnormal processing of 
this vitamin in cancer patients [101]. High-affinity riboflavin-binding Igs 
have been isolated from the serum of two patients with multiple 
myeloma [103,104]. The existence of riboflavin-binding Igs may represent a 
response of the immune system to a stimulus by riboflavin or a flavin 
derivative. A possibility is that a flavoprotein containing covalently 
attached FMN or FAD (flavin alone is to small to be immunogenic) has 
elicited the production of antibodies [105], of which some bind to the 
flavin moiety. Whether by accident or design, the presence of these Igs has 
the potential to affect flavin metabolism. The multiple myeloma patient 
from whom riboflavin-binding monoclonal antibody was isolated did not 
show signs of riboflavin deficiency, but by urinary excretion the riboflavin 
level was decreased in this individual [106]. Since an increase in riboflavin 
binding levels has been noted in patients with certain types of cancer, the 
decreased urinary excretion that has been demonstrated in several types of 
cancer may be a mechanism to keep the riboflavin in circulation due to 
protein binding. On the other hand, the investigations of Stoppini et al 
[107] have not revealed any additional physiological function for these 
IgGs, so the existence of these high-affinity Igs might indeed be a 
coincidence. 
2.3. Flavin-protein interactions and their influence on the flavin redox 
potential 
The versatility of the flavin is regulated by its protein environment. 
This protein environment causes the binding and catalytic steps to be 
specific and controls the kinetics and thermodynamics of the electron 
transfer processes. The thermodynamics of the electron transfer are 
reflected in the redox potential. The redox potential indicates the tendency 
of a molecule to acquire electrons and become reduced or donate electrons 
and become oxidized. For flavin different redox potentials can be 
distinguished: E^ corresponding to the quinone-semiquinone potential, 
E2, corresponding to the semiquinone-hydroquinone potential and 
E„'(=Ei+E2/2), that reflects the quinone-hydroquinone potential [95]. For 
free flavin the semiquinone form is thermodynamically destabilized 
which is demonstrated in a more negative E1 and a relatively positive E2. 
In oxidases and flavodoxins the semiquinone is stabilized by specific 
interactions with the protein surrounding it. The redox potentials of a 
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given flavoenzyme may give a clue in determining which molecule the 
enzyme can use as electron donor or acceptor in redox catalysis; variable 
redox potentials allow different functions for flavoproteins. However, the 
relation between the redox potentials of the diverse flavoproteins and 
their catalytic function is not yet clear. 
The redox chemistry of the flavin is restricted to the isoalloxazine 
nucleus. Ring C of the three-membered ring system is electron-deficient 
and can be viewed as an "electron sink". In thermodynamic terms, any 
interaction which tends to lower its electron density will increase the 
redox potential and the other way round. The nitrogens N(5) and 
especially N(l) act as the redox centre of the flavin. Changes in the local 
environment around these two atoms may result in relatively large 
changes in the redox potential of the flavin. Other forces acting on the 
three-ring system, such as steric effects or hydrogen bonds, can also 
profoundly affect the flavin redox potential by hindering the folding of 
the molecule over the N(5)-N(10) axis. Ring A plays an indirect role in the 
reduction a n d / o r reoxidation of the flavin moiety by serving as 
polarizability source for the changes occurring in the redox-active N(l)-
C(10a)-C(4a)-N(5) region, in that way fine-tuning the modulation of the 
redox potential [94]. For instance, in glutathione reductase there is an Arg 
residue located close to the C(8) methyl group inducing polarization that 
could influence the rest of the isoalloxazine [108]. For oxidases, X-ray 
crystallographic structures show positive residues of the protein 
interacting with ring C. Glycolate oxidase [109] has a positively charged 
lysine and both glucose oxidase [110] and cholesterol oxidase [111] have 
histidine residues in the vicinity of ring C. In all cases the flavin is well 
buried in the protein, rigidly fixed by hydrogen bonds, with only the 
region around N(5) accessible to solvent. 
O x i d a s e s s h u t t l e b e t w e e n the f l avoqu inone and the 
flavohydroquinone. However, the thermodynamics of these enzymes 
involves stabilization of the flavosemiquinone (reflected in an Ea 
positively shifted and an E2 negatively shifted compared to that of free 
flavin) which does not fit with the catalytic two-electron transfer. 
Stankovich and coworker have shed light on this, primarily with their 
studies on D-amino acid oxidase [112,113]. From structural information 
available on oxidases it is known (see above) that there is an amino acid 
side chain that forms a hydrogen bond with N(l) of the flavin ring. This 
hydrogen bond causes a net positive charge on the oxidized enzyme 
(resulting in a more positive potential) which makes the first electron 
easier to transfer and also makes the first electron transfer pH 
independent since no proton has to be transferred along with the first 
electron to neutralize the charge. In contrast, the transfer of the second 
electron is at a more normal potential for flavin and is also pH dependent 
since the one-electron reduced enzyme has a neutral or only slightly 
positive charge. For D-amino acid oxidase it has been found that binding 
of a substrate analogue regulates the first electron transfer by causing a 
negative shift of Ei (i.e. destabilization of the semiquinone) and a positive 
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shift of E2 (i.e. stabilization of the hydroquinone). Thus binding of the 
substrate analogue causes the conformation of the protein around the 
flavin to change and, according to Fitzpatrick and Massey [114], this is due 
to disruption of the hydrogen bond at the N(l) position of the flavin ring. 
Summarizing, binding of substrate causes the enzyme to be further 
"tuned" to a state of "active" conformation. For other oxidases, e.g. 
glucose oxidase and glycolic acid oxidase the protonation and redox 
behaviour are more complex. 
In case of monooxygenases, the redox potential does not seem to 
influence the reactions catalyzed, nor has it yet given clear insight into the 
mechanism of this class of enzymes. 
A distinguishing feature of flavodoxins, an important family of 
electron transferring flavoproteins with FMN as prosthetic group, is the 
very negative E2 value resulting in stabilization of the semiquinone 
compared to the hydroquinone. Ring A of FMN is on the surface of the 
protein and in contact with bulk solvent whereas ring C is buried in a 
relatively apolar binding pocket. The dianion phosphate group at the end 
of the N(10) substituent of FMN (Fig. 1.8) is not compensated by basic 
residues in the protein and therefore interacts unfavorably with the 
negatively charged hydroquinone [115]. This feature combined with the 
unfavorable electrostatic environment provided by solvent-accessible 
surface acidic residues clustered around the FMN [116] and the apolar 
environment of the isoalloxazine nucleus [117] significantly determine 
the destabilization of the hydroquinone. 
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3. Catalytic antibodies 
One of the major challenges for the modern biochemist is to extend the 
repertoire of natural biocatalysts, particularly in view of reactions for 
which no natural catalysts exist. At present the most successful way to 
design and generate a totally new biocatalyst is the generation of a catalytic 
antibody or abzyme (=antifrody enzyme). The immune system's capacity to 
produce high-affinity binding sites for virtually any ligand has been 
successfully exploited in recent years to create these antibodies with 
tailored catalytic specifications. The hypothesis that antibodies, like 
enzymes, could catalyze chemical reactions was proposed by Jencks in 1969 
[118], surprisingly in a textbook. This concept is based on the transition 
state theory that states that enzymes can catalyze reactions by stabilizing 
the transition state of the reaction [119]. Jencks proposed that antibodies 
generated against such a transition state should be able to stabilize it and 
should therefore catalyze the reaction. The development of hybridoma 
technology [1], realizing the production of monoclonal antibodies, was 
necessary to prove Jencks' hypothesis. Immunization with stable template 
molecules that mimic the short-lived transition state of a chemical 
reaction yielded the first catalytic antibodies in 1986 [120,121]. 
While these first catalytic antibodies catalyzed only simple hydrolysis 
reactions, there are now antibodies catalyzing acyl transfers, pericyclic 
processes, eliminations, isomerizations (for a review see [122]), peptide 
synthesis [123,124] and, to a certain extent, redox reactions (see 3.2). The 
present generation can even catalyze reactions that are disfavored or for 
which no natural enzyme catalyst is known, such as the Diels-Alder 
reaction or a Cope rearrangement [125-128]. However, there are still a 
number of challenges in this field: aldol condensat ions, S N 2 
displacements, phosphoryl and glycosyl group transfers and, most 
challenging, the sequence-specific cleavage of peptides and DNA are 
among the challenging reaction types that have not yet been catalyzed by 
antibodies [122]. 
Catalytic antibodies could potentially solve specific practical problems. 
Hydrolytic antibodies might be used to selectively activate prodrugs. For 
this purpose anti-phosphonate antibodies that converted biologically 
inactive esters into their bioactive forms were developed [129,130]. The 
antibodies produced strongly inhibited bacterial growth in in vitro tests. 
Extending this approach to the creation of bispecific antibodies derived 
from a catalytic antibody and a tumor-specific antibody could improve the 
therapeutic efficiency of many cytotoxic agents. A useful practical 
application of hydrolytic antibodies might be their use in the treatment of 
drug addiction. Catalytic antibodies that catalyze the degradation of 
cocaine to yield an inactive metabolite lacking cocaine's stimulating 
properties are a promising example in this respect [131]. In the future 
therapeutic approaches to the treatment of addiction or overdose might 
involve immunization of the host with the transition state analogue or 
direct administration of purified antibodies [132]. 
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At present the crucial problem in the search for catalytic antibodies is 
the very small chance of selecting the desired catalyst. On one hand the 
available antibody pool might not be large enough, on the other hand it 
might be too large to successfully select the one desired antibody. 
Consequently, two goals should be focused on: hapten design and 
screening. To generate highly active catalysts in a single immunization 
step, it will be necessary to elucidate the rules that make one hapten better 
than another. Studies on hapten design are starting to shed light on this 
[133-135]. Screening is a very crucial step in the search for catalytic 
antibodies since the amount of active catalysts in a pool of antibodies can 
be quite low. Clearly, the larger the pool of candidates evaluated, the better 
the chances of identifying highly efficient catalysts and of establishing a 
meaningful correlation between hapten structure and catalyst function. 
Powerful screening methods have been developed in the past few years: 
sensitive immunoassays [136], labeling compounds with fluorescent tags 
[137] and biological selection methods that allow the catalytic activity of 
individual clones to be monitored directly. This last powerful screening 
strategy relies on bacterial molecular biology: the use of bacteria lacking an 
enzyme indispensable to survival; only those bacteria that express an 
antibody having the catalytic properties of the missing enzyme survive 
(for examples see [138,139]). These powerful screening techniques can be 
adapted for the direct selection of catalytic activities out of large phage 
display libraries [140]. 
Nevertheless, even the best catalytic antibodies so far generated are 
much less active than their natural enzyme counterpart. Structural and 
mechanistic studies [141,142] suggest that the modest activity observed in 
most first-generation catalytic antibodies is due to their short evolutionary 
history and imperfect hapten design [122]. Presumably, one-step strategies 
to elicit catalytic antibodies will not be sufficient to select antibodies with 
reasonable turnover rates, simply because the available repertoire will 
never be large enough. Evolutionary strategies, in which antibodies will 
be subjected to rounds of mutagenesis, will contribute significantly to this 
task [143]. Production of antibodies in bacteria (1.4.2) and the use of 
combinatorial libraries of antibodies displayed on phage (1.4.3) will 
definitely play a crucial role with respect to this. Furthermore, improved 
design of transition state analogues will play an important role. 
3.1. Redox active catalytic antibodies 
Enzymes that mediate redox reactions form an important and 
promising class of enzymes for practical applications. These enzymes use 
biological redox cofactors such as flavin (see 2) and heme. To mimic redox 
enzyme activity, antibodies have been generated that catalyze redox 
reactions. However, most of these antibodies use electron donors or 
acceptors different from the cofactors used in nature, for example, the 
periodate-dependent oxidation of sulfide to the corresponding sulfoxide, a 
monoxygenase reaction [144,145]. Other examples are the stereoselective 
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reductions of ketoamides [146] and ketones [147] for which sodium 
cyanoborohydride has been used as an electron-donor. These electron-
donors and -acceptors can not be recycled and must therefore be added in 
large quantities. 
In order to further expand antibody catalyzed redox reactions, strategies 
that allow incorporation of cofactors, that can be recycled, into the 
antibody binding site will have to be used. To this end antibodies have 
been elicited against flavin [148] and heme [149]. In an attempt to mimic 
peroxidase activity, Cochran and Schultz [149] generated antibodies against 
N-methylmesoporphyrine, a transition state analogue for porphyrine 
metallation. These antibodies catalyze the metallation of mesoporphyrine 
IX. One of these antibodies also binds the biologically relevant 
metalloporphyrine iron (III) mesoporphyrine. This antibody-porphyrine 
complex catalyzes the oxidation of several typical chromogenic peroxidase 
substrates [150]. However, this antibody lacks multiple binding sites for 
cofactor and substrate binding (which is a common feature for redox 
enzymes): it only binds the heme and is therefore not substrate specific. 
Nevertheless these studies might be a first step to the development of 
selective antibody-heme peroxidase catalysts. 
Antibodies have also been elicited against oxidized flavin (see 2.1) [148]. 
One of these antibodies causes the redox potential to shift from -206 mV to 
-343 mV. Hence, antibody bound flavin is a stronger reducing agent than 
free flavin. The substrate safranine T (E0 = 298 mV) could rapidly be 
reduced by the antibody-flavin complex (previously reduced by sodium 
dithionite), a process that did not occur with free flavin. However, this 
antibody again lacks the substrate binding site. Moreover, the cofactor was 
not catalytically recycled in the antigen-binding site. 
Antibody catalysis of redox reactions is a complex matter. Strategies 
have emerged for the generation of catalytic antibodies that utilize 
"unna tu ra l cofactors" (like sod ium pe r ioda t e or s o d i u m 
cyanoborohydride). Redox-active heme and flavin binding antibodies 
have also been described. However, neither of these antibodies possesses 
binding sites for substrate as well as the cofactor, nor could the cofactor be 
catalytically reduced in the antigen-binding site. 
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4. Aim of this thesis 
The goal of this thesis is two-fold. Firstly, we want to develop a redox-
active antibody that can bind both a cofactor and a substrate molecule and 
also is capable of recycling a cofactor in its antigen-binding site. Secondly, 
we want to develop a model system to study how the protein-
environment regulates the redox potential and compare this with the way 
natural flavoproteins perform this task. 
To achieve the first goal we chose flavoprotein oxidases (see 2.2.1) as a 
model system. Using hybridoma technology antibodies have been 
generated against a stable reduced flavin analogue that has a benzoyl 
substituent covalently linked to N(5) (chapter 2). These antibodies have 
extensively been characterized by time-resolved polarized fluorescence 
spectroscopy (chapter 2). The benzoyl substituent should create a pocket in 
the antigen-binding site that will both accelerate cofactor recycling and 
serve as a substrate binding pocket. One of these antibodies has been 
studied for catalytical reoxidation of reduced flavin in the antigen-binding 
site (chapter 5). 
In order to contribute to a better understanding of how protein 
environments regulate the flavin redox potential, scFv antibody 
fragments have been generated against reduced as well as oxidized flavin 
using a naive antibody phage display library (see 1.4.3). The direct selection 
of an scFv antibody against oxygen sensitive two-electron reduced flavin 
has been described in chapter 3. Mapping studies of anti-flavin scFvs with 
different flavin analogues, confirmed by molecular modelling studies (see 
1.2.2.1), contribute to a better understanding of how these "artificial" 
protein environments regulate the flavin redox potential (chapter 4). 
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Monoclonal antibodies against two electron reduced riboflavin 
and a quantification of affinity constants for this oxygen sensitive 
molecule* 
Abstract 
In order to create a protein environment that binds preferentially to the 
two-electron reduced form of flavin, monoclonal antibodies have been 
raised against a reduced flavin derivative. Due to the low fluorescence 
quantum yield and visible light absorption and to the instability of 
reduced flavin in an aerobic environment, it is not possible to determine 
the affinities of these antibodies for two-electron reduced flavin using 
standard techniques. Because of its sensitivity, time-resolved fluorescence 
can be used to overcome this problem. This technique has been applied to 
study the binding of two antibodies, an IgGj and an IgM, to reduced 
riboflavin (1,5-dihydroriboflavin) and oxidized riboflavin (riboflavin). 
The affinity of the IgG) is more than 80 times larger for 1,5-
dihydroriboflavin than for riboflavin. From analysis of the dynamical 
parameters of the system it is apparent that the internal motion of 1,5-
dihydroriboflavin bound to IgGi is much more restricted than that of 
riboflavin. In contrast, the affinity of the IgM is only slightly higher for 
1,5-dihydroriboflavin than for riboflavin and the flexibility of binding of 
both flavin redox states in the antigen binding site is almost similar. 
2.1. Introduction 
Flavins mediate a variety of chemical reactions including 
dehydrogenation, electron transfer, activation of molecular oxygen and 
photochemical reactions. This versatility sets flavoproteins apart from 
most other cofactor-dependent enzymes, which, in general, each catalyze a 
single type of reaction [1]. One of the most interesting features of the 
versatile flavin molecule consists of its redox properties which can be 
modulated by the (protein) environment. The redox active part of the 
flavin is the isoalloxazine ring which can exist in oxidized flavoquinone, 
one-electron reduced flavosemiquinone and two-electron reduced 
flavohydroquinone states. The redox potentials of both electron transfer 
steps vary largely among different flavoproteins and depend on the 
chemical nature of the active site in which the isoalloxazine resides. This 
This chapter has been published as: Y. E. Bruggeman, R.G. Schoenmakers, A. Schots, 
E.H.W. Pap, A. van Hoek, A. J.W.G. Visser and R. Hilhorst, Eur. J. Biochem. 234, 245-250, 
1995. 
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property makes the flavin suitable as an electron shuttle in very different 
redox reactions which explains its widespread occurrence in nature [2]. 
The role of the protein environment in modifying the chemical reactions 
arid the redox properties of the flavin is not yet clear. Creating artificial 
protein environments with a predetermined affinity for oxidized and 
reduced flavin and comparing the structural and redox properties of these 
proteins, might contribute to gain more insight in this problem. 
Monoclonal antibodies (mAbs) are very useful tools for this because the 
flavoquinone differs from the hydroquinone in its conformation and 
electronic properties. This enables generation of antibodies specific for 
either the reduced or the oxidized form. Shokat and coworkers have 
indeed shown that it is possible to create an anti-flavin antibody that can 
influence the redox properties of flavin [3]. 
Here we report a strategy to obtain a protein environment which binds 
preferentially the 1,5-dihydroflavin and to develop a method to 
determine the affinity of such an antibody for this flavin. The generation 
of mAbs is hampered by the instability of the flavohydroquinone under 
aerobic conditions. This problem was circumvented through the design of 
a reduced flavin analogue that was not sensitive to reoxidation. Another 
problem is that, in contrast to its oxidized form, reduced flavin possesses a 
low fluorescence quantum yield and visible light absorption [4]. For this 
reason it is difficult to determine dissociation constants for reduced flavin 
using standard (fluorescence) techniques. Because of its sensitivity, 
however, time-resolved polarized fluorescence techniques can be used to 
overcome this problem. Time-resolved fluorescence is one of the very few 
methods to obtain quantitative information on the binding of both 
oxidized and reduced flavin to the antibody molecule. The excited state of 
a fluorophore, such as flavin, has a lifetime in the (sub)nanosecond range. 
Since this corresponds to the timescale of rotational and internal motion 
of the antigen in the antigen binding site, time-resolved fluorescence also 
gives information about the flexibility of the antigen binding as compared 
to the overall or segmental motion of the antibody. 
2.2. Experimental procedures 
2.2.1. Synthesis of hapten and conjugates 
Riboflavin (from Sigma) dissolved in dry pyridine was refluxed for 4 
hours with a fivefold excess of succinic anhydride [5]. After addition of 30% 
(w/v) toluene, the solvent was removed under reduced pressure. The 
residue was dissolved in water and purified with DEAE-Sepharose (batch 
wise). The succinylated riboflavin (Fig. 2.1, R=l) was eluted from this 
material with 1 M NaCl and was conjugated to porcine thyroglobuline 
(Sigma) or BSA fraction V (Boehringer Mannheim) with l-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (Sigma) using general procedures 
(Fig. 2.1, R=2a or 2b, further indicated as 2a and 2b respectively) [6]. After 
conjugation, the flavin was modified on the N(5) position by irradiating 
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Q benzoyl formic acid 
light 
o co2 
R t = CH2(CHOH)3CH2OCO(CH2)2COOH 
R2a = CH2(CHOH)3CH2OCO(CH2)2CONH-PTG 
R2b = CH2(CHOH)3CH2OCO(CH2)2CONH-BSA 
R3a = CH2(CHOH)3CH20CO(CH2)2CONH-PTG 
R3b = CH2(CHOH)3CH2OCO(CH2)2CONH-BSA 
Figure 2.1. Synthesis of hapten and conjugates. 
the flavin-protein conjugate with visible light in the presence of 
benzoylformic acid under anaerobic conditons yielding the N(5)-benzoyl-
N(10)-ribitylsuccinimide ester flavin (Fig. 2.1, R=3a or 3b) [7]. The excess 
benzoylformic acid was removed by dialysis against 0.5% (w/v ) 
ammonium bicarbonate. These hapten-carrier conjugates (indicated as 3a 
and 3b respectively) were freeze dried for storage. 
2.2.2. Monoclonal antibody production, selection and purification. 
Balb/c mice were immunized twice with 3a (Fig. 2.1). Spleen cells from 
these mice were fused to myeloma cells (SP 2/0) [8], according to protocols 
described by Schots and coworkers [9]. Hybridoma clones producing 
antibodies against the modified flavin were selected using an Enzyme 
Linked Immunosorbent Assay (ELISA) against 3b (Fig. 2.1) and BSA alone. 
For this purpose microtiter plates were coated with 100 ul per well of 10 
u g / m l 3b (Fig. 2.1) or BSA in PBS. The wells were blocked with 5% 
skimmed milk powder in PBS. Mouse antibody was detected by alkaline 
p h o s p h a t a s e conjugated rat an t i -mouse an t ibody (Jackson 
ImmunoResearch Laboratories, Inc.). 
Positive hybridoma clones were cloned until stability, whereafter the 
cultures were expanded in flasks (150 cm2). We used Iscove's modification 
of Dulbecco's medium (IMDM) and low IgG fetal calf serum for these 
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cultures. MAbs of the IgM isotype were purified by precipitation with 8.5% 
polyethyleneglycol (MW 6000, Sigma) followed by gelfiltration 
chromatography (Superdex 200 prep grade, Pharmacia). IgG, antibodies 
were purified by thiophilic adsorption chromatography (Affi T™ 
thiophilic agarose, Biozym). All preparations were judged for purity by 
sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). 
Antibody concentrations were determined by measuring the absorbance at 
280 nm assuming A28o=l-25 for 1 mg/ml and a molecular mass of 970 kDa 
for IgM and 150 kDa for I g d [6]. 
2.2.3. Sample preparation for fluorescopic measurements 
Since the fluorescence quantum yield of reduced flavin is very low, a 
minimal concentration of flavin is required to get a proper signal. 
Therefore we chose for titration of a constant amount of riboflavin or 1,5-
dihydroriboflavin with antibody instead of titration of a constant antibody 
concentra t ion wi th variable amounts of riboflavin or 1,5-
dihydroriboflavin. Different amounts of antibody, up to 0.223 mg /ml for 
aRfmodG! and to 0.816 mg/ml for aRfmodM, were mixed with 0.1 and 0.05 
\iM riboflavin respectively. For measurement of 1,5-dihydroriboflavin, 
these solutions were deaerated by flushing with argon and riboflavin was 
reduced with a 30 times molar excess of sodium dithionite. All 
compounds were dissolved in 50 mM sodium pyrophosphate pH 8.0 
containing 150 mM sodium chloride and filtered through a 0.22 |im filter 
(Costar). 
2.2.4. Time-resolved fluorescence and fluorescence anisotropy 
measurements 
Time-resolved fluorescence decays were measured using the time-
correlated single photon counting set up described earlier [10]. Vertically 
polarized light of 444 and 450 nm was used to excite 1,5-dihydroriboflavin 
and riboflavin, respectively. After excitation the polarized fluorescence 
was monitored using a Schott (Mainz, Germany) interference filter (Schott 
557,6 nm, with a full width at half maximum of 12.6 nm) in combination 
with a Schott cut-off filter (OG515). After each sample the background of 
the samples in the absence of antibody and flavin was measured at one 
fifth of the time of the sample acquisition time. Erythrosin B served as a 
reference compound to yield the dynamic instrumental response function 
of the set-up [11]. Erythrosin B shows a single exponential fluorescence 
decay time of 80 ps at 20°C which was the sample temperature used. The 
data were collected in a multichannel analyser (Nuclear Data model 
ND66) using 1024 channels per experimental decay with a time spacing of 
30 ps per channel. For the registration of the fluorescence decays the 
excitation energy was chosen to yield a frequency of fluorescence photons 
of 30 kHz. In this way the signal-to-noise ratios in the fluorescence decays 
of riboflavin and 1,5-dihydroriboflavin were comparable. 
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2.2.5. Data-analysis and calculation of the affinity constant 
The fluorescence decays were analyzed in terms of a continuous 
distribution of decay times by means of the maximum entropy method 
(Maximum Entropy Data Consultants Ltd., Cambridge, UK) of analysis 
yielding the fluorescence lifetime and rotational correlation time 
distributions of the free and bound riboflavin and 1,5-dihydroriboflavin 
[10,12,13]. This method recovers the optimal spectrum of decay times by 
maximizing the Shannon-Jaynes entropy and minimizing the y} statistics 
and has the advantage that a unique solution is found with no a priori 
knowledge of the decay model. 
The time-resolved fluorescence anisotropy (A(t)) of a fluorescent 
molecule in a protein can be adequately described by an expression which 
assumes two independent rotational motions: a rapid internal motion of 
the flavin in the antigen binding site (<|>int) and a slower motion due to the 
overall or segmental motion of the antibody (<t>«,) (the subscript is used to 
indicate that this time is "infinitely long" on the experimental timescale) 
[14]: 
A(t) = [ßiexp(-t/.fcnt) + ß2]exp(-t/(U (1) 
We can define a so-called order parameter S for a fluorescence probe 
attached to the protein. When there is no internal probe motion, the 
probe rotates together with the whole protein and S is equal to unity. 
Depending on the freedom of internal probe motion relative to protein 
rotation, S will be less than unity. The order parameter S can be obtained 
from (see for example [15]): 
S=[ß2/(ßi + ß2)]1/2 (2) 
From S we can estimate the displacement angle y over which the probe 
can move over the line of attachment to the protein (which is considered 
to be the local symmetry axis of the potential well in which the probe 
moves; a further assumption is that the emission transition moment is 
parallel to this symmetry axis) according to: 
S = [l/2cos\|/(cosy + l)]1 '2 (3) 
The internal correlation time <t>jnt is inversely related to the diffusional 
rate constant D via: 
D=(l-S2)/(64.int) (4) 
The fraction of bound 1,5-dihydroriboflavin was calculated from 
anisotropy decays using a fractional analysis approach [16]. We assumed 
that the system is in binding equilibrium and consists of a mixture of only 
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two states: bound and free 1,5-dihydroriboflavin. Provided that the decay 
curves corresponding to free 1,5-dihydroriboflavin and of a sample where 
the majority of the flavin molecules is bound are known, decays 
measured at intermediate binding conditions can be described as a 
combination of both limiting decays. The fraction of bound riboflavin was 
calculated from the decrease of the free riboflavin contribution in the 
rotational correlation-time spectra. The dissociation constant (Kd) was 
then obtained according to the following equations (written out for 
riboflavin): 
_ [riboflavin]free[binding sites]free 
[binding sites]occuPied 
[binding sites]free = n[Ab] - [riboflavin]bound (6) 
where n corresponds to the number of binding sites per antibody 
molecule. 
Combination of equations 5 and 6 gives: 
n[Ab] - [ r ibo f l av in ]^ = Kd. frb^vm]^
 ( ? ) 
[riboflavinjfree 
_ , . r AI i r -1 n • i r • r [riboflavinlbound . ,, 
Plotting n[Ab]-[riboflavmJbound as a function of !L-—— gives the 
[riboflavin]free 
Kd. Since riboflavin and 1,5-dihydroriboflavin are small molecules, all 
binding sites must be available for binding. Therefore it was assumed that 
n=2 for aRfmodG! and n=10 for aRfmodM [17]. 
2.3. Results 
2.3.1. Synthesis of hapten and conjugates 
For mouse immunization we prepared the N(5) substituted reduced 
flavin derivative 3a (Fig. 2.1), since the two-electron reduced 
flavohydroquinone quickly reoxidizes under influence of oxygen. The 
conjugates 2a and 2b (Fig. 2.1) were obtained by conjugation of the 
succinylated riboflavin to PTG and BSA resulting in molar ratios of 44:1 
for PTG and 6:1 for BSA. After reduction in the presence of benzoyl formic 
acid the N(5)-benzoyl-N(10)-ribitylsuccinimide ester flavins 3a and 3b (Fig. 
2.1) both showed an absorption spectrum that is characteristic for reduced 
flavin. 
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2.3.2. Monoclonal antibody production, selection and purification 
After immunization of mice with conjugate 3a and generation of mAbs 
the resulting hybridomas were first screened for binding to the BSA-
conjugate 3b as well as to BSA alone, and then for binding to the BSA-
riboflavin conjugate 2b (Fig. 2.1). 16 mAbs bound to 3b and 2b and not to 
BSA alone. No significant difference in binding to the conjugates 2b and 
3b could be detected, so that at this point we had no indication whether 
these mAbs indeed bound the reduced flavin analogue preferentially. 
Two antibodies of different isotype, the IgGi aRfmodGi and the IgM 
<xRfmodM, were chosen for further investigation. These hybridoma clones 
were grown in larger amounts and purified from tissue culture 
supernatants. 
2.3.3. Time-resolved total fluorescence measurements and analysis 
To study the binding of aRf^ ,^ ! to riboflavin we measured 0.1 uM 
riboflavin incubated with antibody concentrations ranging from 0 to 1.5 
uM. To investigate binding of 1,5-dihydroriboflavin to aRfmodG1 the 
riboflavin in these samples was reduced. Examples of experimental total 
fluorescence decays of free and antibody bound riboflavin and 1,5-
dihydroriboflavin are shown in Fig. 2.2A and C. The fluorescence of 
antibody bound riboflavin exhibits an initial faster decay than the 
fluorescence of free riboflavin. The decay of free and bound 1,5-
dihydroriboflavin shows much more heterogeneity. However, the 
fluorescence decay characteristics of free and bound 1,5-dihydroriboflavin 
hardly differ. 
The total fluorescence decays are analysed using MEM. The lifetime 
distribution patterns for both free and antibody bound riboflavin and 1,5-
dihydroriboflavin are shown in Fig. 2.2B and 2D. The corresponding 
average fluorescence lifetimes obtained are listed in Table 2.1. Free 
riboflavin has a major lifetime of 3.7 ns and two small contributions of 1.7 
and 0.13 ns (Fig. 2.2B, broken line). The two small contributions are 
probably due to self-quenching as a result of a tendency of self-association 
of riboflavin molecules (note that riboflavin does not dissolve in water 
very well). This is confirmed by the fact that a lower riboflavin 
concentration gives a longer average fluorescence lifetime (Table 2.1). 
Upon addition of increasing amounts of mAb the contribution of the 
component at 3.7 ns decreases and two contributions around 0.89 and 0.11 
ns show up (Fig. 2.2B, solid line) which are responsible for the faster 
initial decay. 
The fluorescence lifetime distribution pattern of 1,5-dihydroriboflavin 
is more complex than that of riboflavin (Fig. 2.2D, broken line). This 
complex pattern can be explained by the presence of multiple, non-planar 
conformations of reduced flavin, that interconvert into each other [18]. 
All these substates cause a more complex lifetime distribution than 
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Figure 2.2. Experimental total fluorescence decays and fluorescence lifetime distributions of free 
and aRfmodGl bound riboflavin and 1,5-dihydroriboflavin. In the panels A and B the broken 
curves reflect free riboflavin, in the panels C and D the broken curves reflect free 1,5-
dihydroriboflavin. The solid curves reflect bound species in all cases. In all experiments the 
residuals of the fit were randomly scattered around zero, indicating an optimal fit. 
riboflavin, which has a planar conformation and only shows a main 
nanosecond lifetime. Free 1,5-dihydroriboflavin shows a broader 
spect rum of fluorescence lifetimes than an t ibody-bound 1,5-
dihydroriboflavin (Fig. 2.2D, solid line) which perhaps can be ascribed to a 
more restricted mobility of bound 1,5-dihydroriboflavin. 
2.3.4. Time-resolved fluorescence anisotropy and analysis 
From a fluorescence anisotropy decay one obtains information on 
rotational and internal motions of the fluorophore. After MEM analysis a 
distribution of rotational correlation times i> can be recovered. The 
experimental fluorescence anisotropy decays and corresponding rotational 
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flavin concentration riboflavin 1,5-dihydro-
(|iM) riboflavin 
-
-
aRfmodGj 
oRfmodM 
0.05 
0.1 
0.1 
0.05 
3.69 
3.29 
2.04a 
2.04b 
2.40 
0.53 
0.88 
0.55c 
a
 mixture of 32% bound and 68% unbound riboflavin, 
b mixture of 24% bound and 76% unbound riboflavin. 
c
 completely bound 1,5-dihydroriboflavin. 
Table 2.1. Average fluorescence lifetimes (in ns) of free and antibody 
bound riboflavin and 1,5-dihydroriboflavin. 
correlation time spectra of free and antibody bound riboflavin and 1,5-
dihydroriboflavin are shown in Fig. 2.3. The rotational diffusion of free 
riboflavin results in an ultrafast decay of the fluorescence anisotropy (Fig. 
2.3A, broken line). Upon addition of aRfmodGj the motional freedom of the 
riboflavin is severely restricted, indicating that binding to this antibody 
limits the motional freedom of riboflavin (Fig. 2.3A, solid line). In Fig. 
2.3C the anisotropy decay curves of reduced 1,5-dihydroriboflavin are 
shown. In presence of aRf^jGj the flavin is totally immobilized (solid 
line). Comparison of the solid curves in Fig. 2.3A and C suggests that the 
affinity of aRfmc,dG! for 1,5-dihydroriboflavin is significantly higher. 
Intermediate antibody concentrations gave intermediate fluorescence 
anisotropy decays in both cases (data not shown). 
The rotational correlation time distribution for free riboflavin (Fig. 
2.3B, broken line) shows a main contribution at 0.14 ns which is in 
agreement with earlier results [19]. When antibody is added, a 
contribution of 0 = 1.1 ns and one longer, non-resolved correlation time 
gradually arise, at the expense of the correlation time of free riboflavin 
(Fig. 2.3B, solid line). The contribution at 1.1 ns (<t>int) is due to restricted 
motion of flavin and reflects its flexible binding in the antigen binding 
site. Fab segmental flexibility and tumbling of the whole antibody are 
apparently slower than the timescale of observation [20,21] and therefore 
result in a contribution at infinite time ($00). 
The rotational correlation time distribution pattern of free 1,5-
dihydroriboflavin is more complex than that of riboflavin (Fig. 2.3D, 
broken line). There is a main contribution at 0.3 ns (58%) which is in fair 
agreement with the value obtained for free reduced flavin 
mononucleotide (FMN) [10]. The other contributions are ascribed to self-
association of 1,5-dihydroriboflavin molecules, since at lower 1,5-
dihydroriboflavin concentrations the distribution pattern approaches that 
of free reduced FMN which is much better soluble in water. 
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Figure 2.3. Experimental fluorescence anisotropy decays and rotational correlation time 
distributions of free and oRfmodGl bound riboflavin and 1,5-dihydroriboflavin. In the 
panels A and B the broken curves reflect free riboflavin, in the panels C and D the broken 
curves reflect free 1,5-dihydroriboflavin. The solid curves reflect bound species in all cases. 
In all experiments the residuals of the fit were randomly scattered around zero, indicating 
an optimal fit. The spike at 100 ns corresponds to the infinite anisotropy and will be refered 
to as (j)~. For both free riboflavin and free 1,5-dihydroriboflavin no §<*> was observed. 
Upon addition of increasing amounts of antibody the rotational 
correlation time spectra gradually change from the initial free to the final 
bound situation represented by the curves in Fig. 2.3D. The peak at 0.4 ns 
(<t>int) reflects rapid internal motion of the flavin in the antigen binding 
site and the contribution at <|>oo is again the result of a superposition of Fab 
segmental flexibility and tumbling of the whole antibody. Inspection of 
Figures 3 B and D reveals that at the highest antibody concentration still 
44 
Monoclonal antibodies against two electron reduced riboflavin 
antibody antigen S \|f (°) « t W ^ ) D^s" 1 ) 
ocRfmodGl 
aRfmodGl 
aRfmodM 
aRfmodM 
riboflavin 
1,5-dihydro-
riboflavin 
riboflavin 
1,5-dihydro-
riboflavin 
0.59 
0.93 
0.70 
0.77 
62 
24 
54 
45 
1.1 
0.5 
1.4 
1.1 
0.10 
0.05 
0.06 
0.06 
Table 2.2. Geometric and dynamic analysis of fluorescence anisotropy of antibody-
bound riboflavin and 1,5-dihydroriboflavin. 
free riboflavin is present, whereas all 1,5-dihydroriboflavin has been 
bound. 
For the IgM aRfmodM we obtained basically similar results, but a 
relatively higher antibody concentration was needed to bind all 1,5-
dihydroriboflavin and it was not possible to bind all riboflavin. 
The rotational correlation time distribution of antibody-bound flavin 
gives information about the motional freedom riboflavin in the antigen 
binding site. From the relative contribution of the internal motion (<t>mt) 
with respect to <j>oo one can derive the so-called order parameter S, defining 
the angular displacement \\i of the riboflavin in the antigen binding site. 
The internal rotational correlation time <|>mt and the order parameter S 
define the diffusion constant D of this reoriental motion (see 
Experimental Procedures). These parameters are collected in Table 2.2 for 
a R f m o d G 1 as well as for <xRfmodM bound riboflavin and 1,5-
dihydroriboflavin. From the order parameter S it is clear that the motion 
of 1,5-dihydroriboflavin bound to aRfmodGj is more restricted than that of 
flexibly bound riboflavin. In addition, the motional dynamics of aRfmodGi 
bound riboflavin are larger than for 1,5-dihydroriboflavin (reflected in D, 
see Table 2.2). In contrast, the order parameters for riboflavin and 1,5-
dihydroriboflavin when bound to aRfmodM reveal that in this case there is 
only a slight difference in the flexibility of binding. 
2.3.5. Determination of affinity constants 
The slow anisotropy decay of 1,5-dihydroriboflavin in the presence of 
aRfmodG1 (Fig. 2.3C) strongly suggests that all reduced riboflavin is bound. 
The fluorescence anisotropy decay of 1,5-dihydroriboflavin in the presence 
of ccRfmodM is the same, indicating that here too all 1,5-dihydroriboflavin is 
bound. This implies that we can assign curves corresponding to free and 
completely bound reduced riboflavin and therefore we are able to 
calculate the fractions of bound and unbound flavin using fractional 
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Kd(riboflavin) Kd(l,5-dihydro-
(|iM) riboflavin) (|xM) 
aRfmodM 27 16 
aRfmodGl 5.8 0.071 
Table 2.3. Dissociation constants for binding of 
aRfmodM and aRfmodGl to Rf and 1,5-dihydro-
riboflavin. 
analysis [16]. The reduced x2 values obtained from these analyses indicate a 
very good quality of the fits (0.99<x2<1.07 for aRf^jGj and 0.99<x2<1.41 for 
«RfmodM)-
For riboflavin we could not define a population in which all the flavin 
was bound, impeding fractional analysis. The rotational correlation time 
spectra of free and bound riboflavin, however, are less complicated and it 
is therefore possible to use the relative contribution of free riboflavin as 
an extent of the fraction of free riboflavin present in the solution (Fig. 2.3B 
for aRfmodGj). The contribution of the rotational correlation time at 0.14 ns 
was normalized to the initial anisotropy of 0.38 [22]. This approach allows 
the determination of affinity constants for weakly bound riboflavin, 
circumventing the problem that saturation of binding sites could not be 
reached. 
The dissociation constants are calculated according to equation 7 (Table 
2.3). Since the error in these values is estimated to be less than 10% we 
indeed have succeeded in obtaining antibodies with a higher affinity for 
1,5-dihydroriboflavin. 
2.4. Discussion 
The fluorescence decay characteristics of free and aRfmodG! bound 1,5-
dihydroriboflavin hardly differ. This is remarkable because the majority of 
the 1,5-dihydroriboflavin is bound. This indicates that the local 
environment of 1,5-dihydroriboflavin when bound is not very different 
from that of 1,5-dihydroriboflavin in aqueous solution. 
From MEM analysis of the fluorescence of 1,5-dihydroriboflavin and 
riboflavin in binding equilibrium with both investigated antibodies, two 
rotational correlation times, a short <|>int and a long <$><x>/ have been 
obtained. Because of the relatively shortfluorescence lifetimes of 
riboflavin and 1,5-dihydroriboflavin it is not possible to dissect the exact 
origin of <t>oo. Previously reported studies, however, on depo la r i z ing 
motions of dansyl bound to IgM and IgG antibodies, ascribe this motion to 
wobbling of the Fab subunits (segmental flexibility) rather than tumbling 
of the whole antibody molecule [20,21]. Moreover, this global tumbling 
should have little influence on the decay of anisotropy if the rate of 
intramolecular flexible motion is significantly larger than that of overall 
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tumbling and if this motion occurs over a sufficient angular range to 
depolarize light considerably. 
Comparison of the fluorescence anisotropy decays of aRfmodGj bound 
riboflavin and 1,5-dihydroriboflavin already suggests that at an antibody 
concentration where 1,5-dihydroriboflavin is clearly totally immobilized, 
riboflavin is only partly bound. Further analysis reveals that both the 
aRfmodG1 and the aRfmodM have a higher affinity for 1,5-dihydroriboflavin 
than for riboflavin. Comparison of the affinities of both antibodies for 1,5-
dihydroriboflavin shows an overall higher affinity of the lgGl aRf^jGj for 
both riboflavin forms. The affinity of aRfmodG! for 1,5-dihydroriboflavin is 
typical for antibodies after the second immune response. The affinities of 
the IgM aRfmodM for both flavin forms are low and typical for IgM 
antibodies that generally have low affinity for the antigen since they are 
formed prior to affinity maturation. From the dynamic and geometric 
parameters we conclude that binding of 1,5-dihydroriboflavin to aRfmodG1 
is less flexible than binding of riboflavin so that not only the affinity for 
this reduced flavin form is higher but also the specificity. For the IgM this 
difference in flexibility of reduced or oxidized flavin binding is less 
evident. When we consider the IgM as a product of the primary immune 
response and the IgGj as a product of the secondary response, these results 
show that during affinity maturation not only the affinity for 1,5-
dihydroriboflavin increases but also the specificity of binding to this 
molecule is strongly improved. 
In ELISA experiments (results not shown) we can not distinguish 
between binding to the riboflavoquinone and the N(5)-benzoyl-N(10)-
ribitylsuccinimide ester flavin that served as hapten and represents the 
riboflavohydroquinone form. This is not surprising because, although a 
powerful method, limitations and artefacts have been reported for ELISA 
[23-25]. Not only the fact of not being able to distinguish between both 
riboflavin forms is a drawback of using the ELISA method for this system, 
but in case of the IgM it is almost impossible to determine the, in general, 
weak affinities of such large, multivalent molecules on a surface. Time-
resolved fluorescence allows us to obtain quantitative information on the 
binding of both riboflavin and 1,5-dihydroriboflavin to the antibody 
molecule. 
2.5. Conclusion 
Time-resolved polarized fluorescence spectroscopy proves to be an 
excellent technique to study binding of flavoquinone and, in particular, 
flavohydroquinone to these antibodies. This method not only allows us to 
determine the affinity for both flavin forms but also gives information 
about the specificity and flexibility of the binding. Moreover, because of 
the high dynamic range, also weak affinities can be determined from 
analysis of rotational motion. 
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Phage antibodies against an unstable hapten: oxygen sensitive 
reduced flavin* 
Abstract 
It is difficult to raise antibodies against haptens and antigens that are 
unstable under the physiological conditions of the serum. Here we have used 
a phage antibody library to isolate antibody fragments against oxygen 
sensitive reduced flavin, by selection of the phage under anaerobic and 
reducing conditions at pH 5 and a pre-elution step with the oxidized flavin. 
The binding of the reduced hapten to one of the antibody fragments was 
characterised by time-resolved polarised fluorescence, and shown to be 
highly specific for the reduced flavin. 
3.1. Introduction 
The use of large repertoires of antibody fragments displayed on phage has 
allowed the isolation of antibodies of different binding specificities without 
the need for immunization (for a review see [1]), including those that are 
difficult to raise by immunization, for example human self-antigens [2,3] or 
highly conserved intracellular proteins [4]. Here we have explored the use of 
this technology for isolation of antibodies binding to compounds that are 
unstable under physiological condtions. 
Flavin, a cofactor in many redox enzymes and electron transfer proteins 
(for a review see [5]), appears to be an excellent model. The flavin molecule 
can exist in oxidized, one-electron-reduced and two-electron-reduced states 
The reduced states are not stable under aerobic conditions. At physiological 
pH (7.2) two-electron-reduced flavin is present as a mixture of two ionization 
states (the pKa of the N(l) of is 6.7 (see Fig. 3.1)). Because two-electron-
reduced flavin differs from oxidized flavin in its conformational and 
electronic properties [6,7], antibodies can discriminate between both forms 
[8,9], and it is possible to prepare mouse monoclonal antibodies to the two-
electron-reduced flavin after immunisation with oxygen-stable analogues [8]. 
However, using phage technology, it should be possible to make 
antibodies against two-electron-reduced flavin directly, by undertaking the 
selection process under anaerobic and reducing conditions at a non-
physiological pH. We describe the use of a "single pot" phage library of 
synthetic scFv fragments [4] to isolate antibody fragments against the 
reduced flavin, and time-resolved polarized fluorescence to characterise 
This chapter has been published as: Y. E. Bruggeman, A.A. Boogert, A. van Hoek, P. T. 
Jones, G. Winter, A. Schots and R. Hilhorst, FEBS Lett. 388, 242-244,1996. 
51 
Chapter 3 
COOR COOR 
(CH2)4 N a - (ÇH2)4 
* V ^ N ^ O dithionite \ ^ \ ^ N ^ ~ ^O 
o 
Flox 
Figure 3.1. Structures of Flred arid Flox. R = H for free flavins, R = BS A for conjugates. 
flavin binding to the selected fragments and to get insight in the flexibility of 
bound flavin [8]. 
3.2. Experimental procedures 
3.2.1. Phage selection 
A "single pot" human synthetic phage-antibody scFv library [4] was used 
for phage selection. The library was rescued with M13K07 helper phage [10] 
(Pharmacia) and phage particles were purified using polyethylene glycol 
(PEG) [11]. 
Immunotubes (Nunc; Maxisorb, 75x12 mm) were coated overnight at room 
temperature with 250 ug/ml N(10)-5'-carboxybutyl-flavin (Flox, gift of J. 
Santema) conjugated to BSA (Flox -BSA, 8 Flox molecules per BSA molecule) in 
PBS and blocked with 2 % skimmed milk powder in PBS for 2 hours at 37°C. 
After washing 3 times with PBS the empty tube was transferred to an argon 
atmosphere in an anaerobic chamber (Miller Howe Ltd., England). Flox was 
reduced to N(10)-5'-carboxybutyl-l,5-dihydroflavin (Flred) by 10 mM 
sodiumdithionite in 100 mM sodiumphosphate, 150 mM NaCl, pH 5.0 
(NaPi/NaCl pH 5.0). All buffers were deaerated by flushing with argon 
before transfer into the anaerobic chamber. 
For the first round of selection 1013 transducing units of phage were PEG 
precipitated. The pellet was transferred to the anaerobic chamber and 
resuspended in 4 ml NaPi/NaCl pH 5.0 containing 1 mM sodiumdithionite 
and 2% skimmed milk powder. The phage were incubated in the Flred-coated 
tube for 2 hours during which period the tube was manually rotated 
repeatedly. After each round of selection the tube was washed 20 times with 
NaPi/NaCl pH 5.0, 0.1% Tween 20, 0.1 mM sodiumdithionite and 20 times 
with NaPi/NaCl pH 5.0, 0.1% dithionite. The library was subjected to four 
rounds of panning. In the first three rounds the phage were eluted with 1.5 
ml 0.1 mM Flred (a solution of FL,X in NaPi/NaCl pH 5.0 was deaerated, 
transferred to the anaerobic chamber and reduced with dithionite). Eluted 
phage were amplified as described by Marks et al [12]. In the fourth round 
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two tubes coated with Flred-BSA were panned with phage from the third 
round. One tube was eluted with 0.1 mM Flred, the other was pre-eluted with 
0.1 mM carefully deaerated Flox followed by elution with 0.1 mM Flred. 
3.2.2. Phage ELISA 
Single ampicillin resistant colonies of E.coli TGI infected with eluted 
phage from the fourth round were assayed for binding to Flred and Flox in an 
ELISA. Two ELISAs were performed simultaneously, one under aerobic 
conditions (F10X-ELISA), the other in the anaerobic chamber (Flred-ELISA). 
After coating two plates with BSA-F10X, the "Flred-ELISA plate" was 
transferred to the anaerobic chamber. For both ELISAs all steps were carried 
out in NaPi/NaCl pH 5.0. For the Flred-ELISA 0.1 mM sodiumdithionite was 
present in all steps to reduce flavin and remove traces of oxygen. After the 
last wash step the Flred-ELISA plate was removed from the anaerobic chamber 
and both plates were developed simultaneously. 
Binding of phage-antibody to antigen was detected with mouse polyclonal 
anti-M13 antibody and alkaline phosphatase-conjugated rat-anti-mouse 
antibody (Jackson Immuno Research Laboratories Inc.). Readings were taken 
by substracting the A620 from the A405 after 1 hour incubation at room 
temperature. Clones were considered specific for Flred (or Flox) if the difference 
in absorbance reading between corresponding wells on the two ELISA plates 
was more than 0.4 (on a scale of 1.8). Clones with a difference of less than 0.4 
were considered cross-reacting. 
3.2.3. Expression, purification and sequence analysis 
Clone txFlred5 was subcloned into pUC119SfiNotMycHis using standard 
recombinant DNA techniques. Expression as a soluble scFv and purification 
were performed as described by Griffiths et al [13]. 
For sequencing, clone aFlred5 was transferred to from TGI to DH5a. DNA 
purified with Qiagen Plasmid Midiprep (Qiagen Inc.) was used as template 
in sequencing reactions. Sequencing reactions with fluorescent dATP 
(AutoRead™ Sequencing Kit, Pharmacia Biotech) were carried out according 
to the manufacturer's instructions using standard M13 primers. The 
sequencing reactions were analysed on an A.L.F. DNA Sequencer (Pharmacia 
Biotech). 
3.2.4. Analysis of affinity and specificity 
Affinity constants for Flred and Flox were determined by time-resolved total 
fluorescence and fluorescence anisotropy in NaPi/NaCl pH 6.0 and pH 7.5. 
3 |iM Flred was titrated anaerobically with scFv concentrations ranging over 0-
5 times molar excess of scFv as compared to Flred. 0.05 nM Flox was titrated 
with 0-6 times molar excess of scFv. Measurements, data analysis by the 
Maximum Entropy Method and calculation of the order parameters were 
performed as previously described [8]. The fractions of free and bound flavin 
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in solution were calculated from the decrease of the free Flred contribution in 
the rotational correlation time spectra. Affinity constants were obtained by 
fitting data to: 
Hbound = (A0 + Ho + Kd - ((A0 +H0 +Kd)2 - 4HoAo)V2 )/2 
where Ho corresponds to the total hapten concentration and Ao to the total 
scFv concentration. 
The affinity constant for Flox (in PBS) was determined by competitive 
ELISA as described in [14]. 
3.3. Results 
3.3.1. Selection for hapten binding 
The goal of this study was the generation of antibody fragments against 
oxygen sensitive reduced flavin. After coating with (oxidized) 5'-
carboxybutyl-N(10)-flavin-BSA (F10X-BSA, Fig. 3.1) an immunotube was 
transferred to an anaerobic chamber where the conjugated flavin was 
reduced to l,5-dihydro-5'-carboxybutyl-N(10)-flavin (Flred, Fig. 3.1). The 
selection was performed at pH 5, where N(l) is protonated (pKa = 6.7). For 
selection of Flred binders, the phage library [4] was subjected to rounds of 
affinity selection with elution of the bound phage by Flred. However at the 
end of the fourth (and final) round, one of the two tubes of bound phage was 
pre-eluted with Flox, then eluted with Flred (see Materials and Methods). This 
proved essential to remove cross-reactive phages since the pre-eluted fraction 
contained no cross-reactive phages whereas in the other fraction about 50% of 
the phages were cross-reactive. 
DNA sequence analysis of the clones giving the best signal to Flred revealed 
that at least three different clones had been selected. One of the clones 
(aFlred5),comprised the VH segment DP-32 [15], with CDR3 of 12 amino acids 
(GWVNVKVSKNPL). The library we used has an unmutated light chain as 
described by Hoogenboom et al [16]. 
3.3.2. Characterization ofscFv fragments 
The clone <xFlred5 was further characterised as a soluble scFv fragment. To 
facilitate purification, <xFlred5 was subcloned into the pUC based vector 
pUC119SfiNotMycHis (lacking the gene III insert but harbouring a 
hexahistidine tag for purification and a cmyc tag for detection) for soluble 
expression. This scFv was purified with a yield of 600 ng/1. 
Binding of Flred to aFl red5 was studied by time-resolved polarized 
fluorescence. The rate of depolarization of emitted light reflects the rotation 
of the probe on a nanosecond timescale. The rotational correlation times ($), 
calculated from such experiments, can be used to quantify binding and to 
obtain information about the flexibility of the fluorescent probe. Reduced 
flavin was titrated with aFlred5 at pH 6 where the N(l) of F l ^ is protonated 
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<t>(ns) 
Figure 3.2. Rotational correlation time distributions of free and aFlrecj5-bound Flrecj and Fl0x 
at pH 6.0. A) Curve a: free F l r e d , curve b: Fl f ed : aFl r e d5 = 1: 0.6, curve c: Fl r e d : aFl r e d5 = 1: 
2.4. B) Curve a: free Fl0x - curve b: Flox : ocFlred5 = 1: 2.3, curve c: Flox : aFlred5 = 1: 4.0. 
(as in the selection) and at pH 7.5 where N(l) is negatively charged. In both 
cases the Flred fluorescence increased upon binding to ocFlred5, presumably 
because the constraint induced by binding to the antibody restricts the 
number of accessible conformational states of Flred [17]. 
A typical example of a distribution of rotational correlation times, obtained 
after analysis of time-resolved polarized fluorescence decays, is shown in Fig. 
3.2A. Free Flred (curve a) shows a main contribution at 0.07 ns. The 
contribution at 0.14 ns is ascribed to self-association of Flred molecules [8]. 
Upon addition of aFlred5 the motional freedom of Flred becomes more 
restricted as is reflected in a contribution (<|>inl) of 1-3 ns. This value reflects 
flexible binding of Flred in the antigen binding site (examples are shown in 
Fig. 3.2A, curve b and c). Affinity constants for Flred were calculated from the 
decrease of the free Flred contribution in the rotational correlation time spectra 
(Table 3.1). 
Tumbling of the whole scFv (tyxFv) appears to be slower than the timescale 
of observation, and results in a contribution at infinitely long time ($J) (Fig. 
3.2A, curve b and c). This was unexpected as the rotational correlation time of 
a scFv molecule can be calculated according to Visser [18] as 10-20 ns. It 
appears that this discrepancy may be due association of scFv molecules by 
hydrophobic interactions in the presence of salt, as in experiments performed 
in the absence of NaCl <t>scFv shifts to about 20 ns (data not shown). 
Binding of ocFlred5 to Flox was also studied at pH 6.0 and 7.5 by time-
resolved polarized fluorescence. No binding could be detected under the 
experimental conditions used in fluorescence experiments (Fig. 3.2B), 
suggesting that the affinity of ocFlred5 for Flox is low. Competitive ELISA had to 
be used to determine an affinity constant (Table 3.1). This experiment was 
performed in PBS at pH 7.2, since the ionization state of Flox is identical at pH 
6.0 and 7.5. 
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pH Kd(Flred)(|xM) Kd(Flox)(uM) S(Flred) 
7.5 0.6±0.06 100±10* 0.3910.05 
6.0 4.0±0.4 0.61±0.11 
* pH 7.2 
Table 3.1. Affinity constants (Kd) and order parameters (S) for binding of 
ctFlred5 to Fired and Flox. 
3.4. Discussion 
By use of phage display technology we were able to make antibodies with 
high binding specificity to haptens that are unstable in physiological 
conditions, and this may obviate the need for synthesis of stable analogues. 
The antibody fragment aFlred5 was highly specific for unstable Flred compared 
with stable Flox (by a factor of 25-160 fold, depending on the pH). In this case 
the binding specificity was fashioned in two stages; firstly during the 
selection process by binding of the phage to Flred under anaerobic and 
reducing conditions; and secondly by pre-elution of the bound phage with 
Flox to remove cross-reactive phages. 
The binding affinity of scFv aFlred5 for Flred (Table 3.1) is similar to those of 
other antibodies isolated from this library [4]. Although phage antibodies 
were selected (at pH 5.0) against Flred protonated at N(l), the affinity of <xFlred 
for Flredis higher at pH 7.5 (Table 3.1). In principle, this could reflect pH-
dependent changes in conformation and /or charge in either the hapten or the 
antibody. Upon increasing the pH, the hapten adopts a negative charge on 
the pyrimidine nucleus of the flavin resulting in a redistribution of electron 
density [7] whereas the geometry of the hapten is similar in both ionization 
states [6]. As indicated by the order parameters (Table 3.1), flexibility of Flred 
in the antigen binding site is more restricted at the lower pH. This decrease in 
flexibility combined with an increase in affinity is counter-intuitive. We 
suppose that the enhancement of electrostatic interactions is at the expense of 
other interactions that anker the flavin to the antibody. 
The success of this strategy to select antibodies against haptens that are 
unstable in the physiological conditions of the serum suggests further 
possibilities. For example, it may allow the selection of antibodies against 
conformations of proteins unstable at physiological pH, or against haptens 
stabilised by co-solvents or in the presence of reactive chemical species 
(potentially useful for the generation of catalytic antibodies), provided that 
the infectivity of the phage can be maintained. 
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Regulation of the flavin redox potential by flavin binding 
antibodies* 
Abstract 
Single chain Fv antibody fragments binding different flavin forms (aFl0X 
and aFlre(i5) have been generated from an antibody phage display library 
in order to study how a protein environment regulates the redox 
potential, starting from a protein other than a natural flavoprotein. These 
"flavobodies" are characterized by time-resolved and steady-state 
fluorescence spectroscopy as well as competitive ELISA methods (mapping 
of the antigen binding site) and molecular modelling. The 3-dimensional 
models of the antigen binding sites are in line with the experimental 
results. Binding of aFl red5 to flavin increases the redox potential, mainly 
due to an arginine residue interacting with the flavin N(l). Thus ctFlred5 
shows an "oxidase-like" redox potential behaviour, confirming the idea 
that positively charged residues in the vicinity of N(l) increase the redox 
potential. The flavobody aFl0 X is the most interesting result of this 
approach: this flavin-binding antibody, that does not resemble a natural 
flavoprotein, shows that when the pyrimidine like nucleus of the flavin is 
not involved in binding, the redox potential is not significantly affected. 
4.1. Introduction 
Flavin acts as cofactor in many redox enzymes and electron transferring 
proteins. These flavin-containing enzymes catalyze a wide variety of 
biochemical reactions varying from oxidase to dehydrogenase and 
monooxygenase type of reactions. This versatility sets flavoproteins apart 
from most other cofactor-dependent enzymes which, in general, only 
catalyze a single type of reaction [1]. The redox-active part of the flavin is 
the isoalloxazine ring which can exist in oxidized flavoquinone, one-
electron reduced f lavosemiquinone and two-electron reduced 
flavohydroquinone states. For flavin different redox potentials can be 
distinguished: Eu corresponding to the quinone-semiquinone potential, 
E2, corresponding to the semiquinone-hydroquinone potential and 
E0 '(=E1+E2/2), which reflects the quinone-hydroquinone potential [2]. 
These redox potentials depend on the nature of the active site in which 
the flavin resides and vary largely among different flavoproteins [3]. The 
role of the protein environment of the flavin cofactor in modulating the 
This chapter has been submitted by Y.E. Bruggeman, A. Honegger, H. Kreuwel, A.J.W.G. 
Visser, C. Laane, A. Schots and R. Hilhorst 
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o o 
flavin 1,5-dihydroflavin 
Flox (CH2)4-COOH 
riboflavin ribityl 
FMN ribityl-phosphate 
Fig. 4.1. Structures of flavin analogues used. 
redox potential is still not properly understood. Here we have investigated 
the structural and redox properties of monoclonal antibodies elicited 
against oxidized and two-electron reduced flavin and compare these with 
"natural" flavoproteins. 
The isoalloxazine moiety of the flavin is amphipatic consisting of a 
hydrophobic benzene-like part (ring A, Fig. 1) and a hydrophilic 
pyrimidine-like part (ring C, Fig. 1). It is the N(5) atom in ring B which is 
particularly responsible for the redox properties of the flavin: N(5) is 
electron-deficient and therefore this is the site where the electrons enter 
the isoalloxazine [4]. The negative charge is spread over C(4a), N(5), N(10) 
and N(l) [5]. The degree to which this negative charge is stabilized or 
destabilized is an important factor governing the redox potential: a 
positive charge in the protein around ring C will contribute to increase the 
redox potential, whereas a negatively charged or hydrophobic 
environment will decrease it. This is clearly shown in the X-ray structures 
of several flavoprotein oxidases: glycolate oxidase [6] has a positively 
charged lysine residue, and both glucose oxidase [7] and cholesterol oxidase 
[8] have histidine residues in the vicinity of ring C, stabilizing the reduced 
flavin. In the one-electron-transferring flavodoxin, however, the flavin 
hydroquinone is destabilized by acidic residues in the vicinity (within 13 
Â) of the N(l) atom of the flavin [9]. 
The apolar part of the flavin, ring A, is either in contact with bulk 
solvent frequently, for example in flavodoxin and cholesterol oxidase, or 
is bound by hydrophobic interactions as in glucose oxidase where C8 
(located in ring A) is sandwiched between a tyrosine and a valine. Ring A 
is often not involved in the reduction and/or reoxidation of the flavin 
moiety and only plays an indirect role by serving as polarizability source 
for the changes occurring in the redox-active N(l)-C(10a)-C(4a)-N(5) 
region, in that way fine-tuning the modulation of the redox potential [10]. 
For instance, in glutathione reductase an Arg residue located close to the 
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C(8) methyl group induces polarization that could influence the rest of the 
isoalloxazine ring [11]. 
This illustrates that the environment of ring C mainly regulates the 
redox potential, suggesting that a protein only binding to ring A should 
hardly influence the redox potential. However, up till now such a 
flavoprotein has not been shown to exist. Monoclonal antibodies, or even 
antibody fragments consisting of the two variable (V) antigen-binding 
domains, offer a way to build artificial protein environments specific for 
different flavin redox states [12-14]. This is possible because oxidized flavin 
differs from reduced flavin in its conformational and electronic 
properties. It might even be possible to generate "unnatural" flavin-
binding proteins that recognize both redox states equally well (i.e. the 
redox potential is not influenced) by generating antibodies that bind to 
ring A. 
In order to contribute to a better understanding of how the protein 
environment regulates the flavin redox potential, we have generated scFv 
antibody fragments (composed of the two antigen-binding domains 
connected by a peptide linker [15]) against reduced [13] as well as oxidized 
flavin from a naive antibody phage display library [16] (in such a library an 
antibody repertoire is cloned on the surface of filamentous bacteriophage; 
antibodies can be selected by panning the library on antigen). Here we 
show that an antibody fragment binding mainly to ring A (aFlox) does not 
influence the flavin redox potential (E0') significantly, whereas an 
antibody fragment binding ring C of reduced flavin (aFlred5) causes a shift 
in E0' of +65 mV. 
4.2. Experimental procedures 
4.2.1. Phage selection 
A "single pot" human synthetic phage-antibody scFv library [16] was 
used for phage selection. Phage were selected for binding to oxidized 
N(10)-5'-carboxybutylflavin (Flox) [13] as described by Nissim et al [16] and 
eluted with 100 mM Flox in PBS. Clones found to give a positive ELISA 
signal were screened by PCR and "fingerprinted" by the frequent-cutting 
restriction enzyme BsfNI as in [17] to identify different clones. Examples of 
clones with different restriction patterns were selected and the 3' ends of 
the heavy chains were sequenced to confirm the fingerprinting as 
described in [13]. 
The selection of a phage antibody (aFlred5) against the reduced N(10)-5'-
carboxybutyl-l,5-dihydroflavin (Flre(j) has been described previously [13]. 
4.2.2. Expression, purification and sequence analysis 
For soluble expression selected clones were subcloned into 
pUC119SfiNotMycHis (lacking the gene III insert but harbouring a 
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hexahistidine tag for purification and a cmyc tag [18] for detection) using 
standard recombinant DNA techniques. A 1 1 culture of E. coli TGI 
harbouring each plasmid was grown to ODéoo of 0.9 and scFv expression 
was induced with ß-isopropylthiogalactoside (IPTG) [19]. After induction, 
the culture was shaken for 3 h at 20°C. Since no scFv could be detected in 
the culture supernatant, scFv was purified from the cells. Cells were 
resuspended in 50 mM phosphate pH 7.5, 500 mM NaCl, 20 mM imidazole 
and 2 mM phenyl-methyl-sulfonyl fluoride (PMSF) and lysed by two 
passes through a French pressure cell at 18000 psi. Cell walls and insoluble 
material were removed from the lysate by centrifugation at 28000xg for 30 
minutes. The scFv was purified by Immobilized Metal Affinity 
Chromatography [20] as described by Griffiths et al [21]. All purification 
steps were performed at 4°C. Purified scFv fragments were judged for 
purity by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-
PAGE). The scFv concentration was determined spectrophotometrically 
using e28o values determined from the amino acid sequences as described 
in [22]. 
For sequencing, DNA purified with Qiagen Plasmid Midiprep (Qiagen 
Inc.) was subjected to PCR cycle sequencing reactions with fluorescent 
dideoxy chain terminators (Applied Biosystems) according to the 
manufacturer's instructions using standard M13 primers. The sequencing 
reactions were analysed on an Applied Biosystems 373 Automated DNA 
Sequencer. Sequence analysis was performed using AutoAssembler 
(Applied Biosystems). 
4.2.3. Mapping of the antigen binding site with flavin (-analogues) 
The antigen binding site of aFl0X was mapped (in PBS, pH 7.2) with 
different flavin analogues (Fig. 1) using different methods: time-resolved 
and steady-state fluorescence spectroscopy as well as competitive enzyme-
linked-immunosorbent assay (ELISA). 
Using competitive ELISA we studied binding of <xFlox to Flox , flavin 
mononucleotide (FMN, Boehringer Mannheim) and riboflavin (Sigma). 
Basically the method described by Friguet et al [23] was followed (omitting 
the pre-incubation step). 
Binding of aFl0x to Flox and Flred was compared using time-resolved 
polarized fluorescence as described in [12]. Both Flox and Flred were excited 
with light of 450 nm. Flavin was titrated with varying antibody 
concentrations. 
As a third method we used steady state fluorescence, based on 
quenching of tryptophan fluorescence by bound hapten [24], to investigate 
binding of aFlo x to FlOX/ riboflavin and FMN. 0.2-0.7 nM concentrations of 
aFlox were titrated with flavin covering a concentration range up to 10 |iM. 
Emission spectra (300-350 nm) were recorded after exciting at 280 nm on a 
SPF 500C Spectrofluorometer (SLM Aminco). Excitation and emission 
monochromator bandwidths were set at 4 nm. 
62 
Regulation of the flavin redox potential 
aFl r ed5 was studied for binding to Flox and Flred using time-resolved 
fluorescence [13] and to Flox [13] and riboflavin using competitive ELISA as 
described previously [13]. 
4.2.4. Calculation of the redox potential 
The shift in redox potential (AE0') for antibody-bound flavin compared 
to free flavin was calculated from Eqn. 1 [25]: 
A C • C • C . R T 1 K ( H o X ) » , 
AEo = Eo (Ab.FI) - Eo (Fi) = — I n (1) 
nF K(Flred) 
where R is the gas constant, T is the temperature (297 K), F is the Faraday 
constant and n the number of electrons transferred in the reaction (here 
n=2). K(F10X ) and K(Flred) are the dissociation constants for Flox and Flreci, 
respectively. 
4.2.5. Computer modelling of the antigen binding site 
Structural models of the VH and the VL domains of ocFlox and ocFlred5 
were derived by homology modelling based on sequence homology with 
antibody structures from the Brookhaven protein database (PDB) [26]. We 
used the Unix Insight II package (version 2.3.0), including the modules 
Biopolymer and Homology, and Discover (version 94.0) both from 
Biosym/MSI (San Diego). The amino acid sequences of the variable 
domains of the antibodies have been used as program input for the 
modelling of the 3-D structures. 
The X VL domain is the same in both scFv fragments [16]. The best 
templates for this VL domain were the VL domain of antibody HIL (PDB 
entry 8fab, 1.8 A resolution) with 66.7% sequence identity, the MCG light 
chain dimer (3mcg, 2.0 Â resolution) with 62.7% sequence identity and the 
VL domain of antibody KOL (2ig2, 1.9 À resolution, and 2fb4, 3.0 À 
resolution) with 58.7% sequence identity. After structural alignment of the 
four potential template structures and careful analysis of the influence of 
local sequence differences on the structures of the the potential template 
molecules, the majority of the coordinates were assigned using 8fab as a 
template. The third complementarity determining region (CDR3), which 
in X chains shows much higher structural variability than in K chains, was 
modelled based on the coordinates of 2ig2. 
The best templates for the VH domain of ccFlred5 were the VH domains 
of the antibody 3D6 (ldfb, 2.7 Â resolution) with 73.6% sequence identity, 
followed by antibody POT (ligm, 2.3À resolution) with 72.5% identity and 
HIL (8fab, 1.8 Ä resolution) with 70.6% sequence identity. Eventually ldfb 
was used as primary template for the modelling of the VH domain. The 
CDR3s of the PDB entries lfvw, 2fvw, 8fab, ligm and 6fab all have the 
same length as that of aFlred5, but these antibodies all have the Arg H94 to 
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Asp H101 salt-bridge [27], which strongly influences the conformation of 
CDR3, while aFlreci5 lacks this salt-bridge. Therefore CDR3 was modelled 
using 2fvb as a template, shortening the loop by 2 residues. The lack of the 
Arg-Asp salt bridge suggests an "open" conformation of this CDR3, in 
which the loop sticks out into the solvent and is highly flexible. 
For the VH domain of ceFlox, the best templates were: the antibody DB3 
(2dbl, 2.9 Â, and also ldba, ldbb, ldbj, ldbk, ldbm) with 54.2% sequence 
identity (but a higher similarity score than the others), followed by 
antibodies TE33 (ltet, 2.3 À) with 56% sequence identity and R19.9 (lfai, 2.7 
À) with 58.7% sequence identity. The model was based primarily on the 
structure of 2dbl. Analogous to aFl r ed5, aFl o x lacks the H94-H101 salt 
bridge and therefore the PDB entries lvfa, lfdl and Imam that have 
CDR3s of similar length could not be used as templates. Here CDR3 was 
modelled by extending the CDR3 of lbaf by two amino acids. 
The relative orientation of the VH and VL domains was determined by 
structural alignment with the Fv fragments of the primary templates. 
After conjugate gradient energy-minimization of the models, the ligands 
(Flo x for aFl0 X and Fl red for aFl r ed5) were docked manually and the 
complexes were annealed in a 20ps molecular dynamics run. Charges were 
assigned consistent with the protonation states expected at pH 7.4. The 
forcefield used was cvff and dynamics and minimization were performed 
without explicit solvent, using a distance-dependent dielectric constant. 
4.3. Results 
4.3.1. Selection of phage antibodies and expression as scFv fragments 
Phage antibodies against oxidized flavin (Flox) were selected using 
standard selection techniques. As revealed by BsfNI fingerprinting and 
confirmed by sequencing, at least four different clones have been selected. 
The clone giving the best ELISA signal to Flox (aFlox) was chosen for 
further characterization as soluble scFv fragment. The selection of the 
reduced flavin binding scFv aFlrecj5 has been described previously [13]. 
The scFv fragments aFlox and aFlrec}5 were purified with yields of 1.5 and 
0.6 mg/1, respectively. 
4.3.2. Sequence analysis 
The primary structures of the variable regions of both antibodies have 
been determined and are shown in Fig. 2. The light chain (L) is the same 
for both antibodies since the library we used has an unmutated light chain 
(IGLV3S1, [17]) as described by Hoogenboom et al [28]. The homology in 
framework (FR) 4 and the end of FR3 of the heavy chain (H) has been 
imposed by the way the library was constructed [16]. ocFlox comprised the 
VH segment [29] DP-14 with an eight amino acid CDR3 and ocFlred5 the VH 
segment DP-32 with a twelve amino acid CDR3. Interestingly, both 
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aFl o x Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S Y G I S W V R Q A P 
aFlred5 Q V Q L V E S G G G V V R P G G S L R L S C A A S G F T F D D Y G M S W V R Q A P 
CDR1 
SO 58 
aFl o x G Q G L E W M G W I S A Y N G N T N Y A Q K L Q G R V T M T T D T S T S T A Y M E 
aFl„d5 G K G L E W V S G I N W N G G S T G Y A D S V K G R F T I S R D N A K N S L Y L Q 
CDR2 
aF1ox L R S L R S D D T A V Y Y C A R T I H W A - - - - L K S W G Q G T L V T V S R 
aFlred5 M N S L R A E D T A V Y Y C A R G W V N V K V S K N P L W G Q G T L V T V S R 
CDR3 
B 
1 24 34 
S S E L T Q D P A V S V A L G Q T V R I T C Q G D S L R S Y Y A S W Y Q Q K P G Q 
CDR1 
50 56 
A P V L V I Y G K N N R P S G I P D R F S G S S S G N T S L T I T G A Q A E D E A 
CDR2 
89 97 109 
D Y Y C N S R D S S G N H V V F G G G T K L T V L G 
CDR3 
Fig. 4.2. Amino acid sequences of aFlox and aFlred5 heavy and light chain domains given in 
the universal one letter code. Note that the light chain is the same in both antibodies. CDR 
regions are shaded. Numbering is according to Kabat [45]. 
antibodies lack the characteristic arginine H94 to aspartate H101 salt bridge 
[27]. 
4.3.3. Mapping of the antigen binding site 
To determine the affinities of ocFlox and aFlred5 for different flavins we 
had to resort to a variety of techniques. Steady state fluorescence, based on 
quenching of tryptophan fluorescence upon hapten binding, usually is the 
method of choice since the affinity can be determined directly in solution 
and the method is very sensitive. Competitive ELISA is another good 
approach but requires more antibody and hapten. We used both methods 
to s tudy affinities for oxidized flavins. However, due to the low 
fluorescence quantum yield and the poor visible light absorption and to 
the instability of reduced flavin in an aerobic environment, it is not 
possible to determine the affinities of these antibodies for two-electron 
reduced flavin using these standard techniques. Because of its sensitivity, 
we used time-resolved fluorescence to investigate binding to reduced 
flavin. 
4.3.3.1. Time-resolved polarized fluorescence 
Binding of Flox and Flreci to both ocFlox and aFl red5 [13] was studied by 
time-resolved polarized fluorescence. The excited-state lifetime (T) of a 
fluorophore in a protein is extremely sensitive to the physical properties 
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Fig. 4.3. Experimental total fluorescence decays and fluorescence lifetime distributions of free 
and otFlox bound Flox and Flred. Grey curves reflect free Flox (A, B) or free Flred (C, D). Black 
curves reflect bound species in all cases. In all experiments the residuals of the fit were 
randomly scattered around zero, indicating an optimal fit. 
of its environment and therefore gives information about the (protein) 
environment in which the fluorescent probe resides. Using time-resolved 
fluorescence one can study this phenomenon at a (sub)nanosecond scale. 
Moreover, time-resolved polarized fluorescence gives information on the 
rotation of the fluorescent probe on this time scale when the rotational 
correlation times (<|>) are derived from the experimental data. 
The total fluorescence decays for free and aFlox-bound Flox and Flred are 
shown in Fig. 3A and B, respectively. The fluorescence of antibody bound 
Flox (Fig. 3A) exhibits a faster decay than the fluorescence of free Flox- The 
fluorescence lifetime distributions, derived from these total fluorescence 
decays, reflect these observations: free Flox (Fig. 3B) has a major lifetime of 
4.2 ns and two small contributions. Upon addition of antibody the 
component at 4.2 ns decreases and two lifetimes at 0.9 and 0.1 ns show up. 
66 
Regulation of the flavin redox potential 
0.20-
0.15-
0.1 -
0.05-
0. 31 
y* 
a A ƒ 
0.1 
I 0free 
1 * i n t A c 
IT b/ \ 
l 
<t>T 
10 
^scFv / 
/ 
i 
Óo 
0 (ns) 
Fig. 4.4. Rotational correlation time distributions of free and otFlox bound Flox. 
Curve a, free Flox ; curve b, Flox : otFlox = 1:140; curve c, Flox : aFlox = 1:280 
(molar ratios). 
The shortening of fluorescence lifetimes indicates a dynamic quenching 
process. 
In contrast to this, the fluorescence decay of aFlox bound Flred is slower 
than that of free Flred (Fig. 3C). The fluorescence lifetime distribution 
patterns corresponding to these curves are more complex than those of 
F l o x (Fig. 3D) as a result of the presence of multiple, non-planar 
conformations that interconvert into each other [30]. This conformational 
instability is also the cause of the low fluorescence quantum yield of 
reduced flavin [31]. The increase in fluorescence upon antibody binding, 
reflected in the increased contributions of longer lifetime components 
(among which a peak at 0.6 ns) indicates a hindered ring inversion of the 
flavohydroquinone due to antibody binding [31]. 
Apart from fluorescence lifetime distributions we also studied 
rotational correlation times obtained from fluorescence anisotropy decays. 
Examples of rotational correlation time distributions are shown in Fig. 4. 
Whereas free Flox shows a single rotational correlation time (<|>free = 0-2 ns), 
we observe 2 more contributions upon titration of Flox with aFlo x : one 
that reflects the internal restricted motion of the flavin in the antigen 
binding site (<t>mt = 1 n s ) a n d a contribution at infinite time (not resolvable) 
that corresponds to tumbling of the scFv itself (<t>ScFv)- However, when 
more antibody is added a fourth contribution at 2.2 ns emerges. We ascribe 
this peak (<|>T) to homo-energy transfer (i.e. energy transfer between two 
identical flavin chromophores). This can be explained by assuming dimer 
formation: scFv fragments secreted from bacteria are often present as both 
monomers and dimers [32], suggesting that the VH and VL domains of 
different chains can pair. The distance between the two antigen binding 
sites of the dimer, i.e. the distance between the two bound flavins, can be 
calculated from the Förster equation (Eqn. 2, see for example [33]): 
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kT = 8.71*10'7R"Vn^krJ (2) 
where R is the distance (in nm) between the two flavins, K is the 
orientation factor describing the relative orientation of donor and acceptor 
transition dipoles (here K=3.29, estimation based on data on lipoamide 
dehydrogenase, taken from [34]), n the refractive index of the intervening 
medium (here n=1.4), kr the radiative rate constant of the donor (0.0556 
ns"1) and J the overlap integral determined from absorption and emission 
spectra (5.53.10~15 M_1cm3) (n, kr and J are taken from Bastiaens et al [35]). 
The rate of transfer (kr) is calculated from the correlation time associated 
with energy transfer ((|>T) (Eqn. 3): 
ki = — (3) 
2<|)T 
Moreover, from the relative contributions (ßint/ ßT and ßSCFv) of each 
antibody-associated peak (font, <t>T and <t>scFv, respectively) to the rotational 
correlation time distribution, the intermolecular angle (8) between the 
flavins (more exactly the angle between the symmetry axes of the potential 
wells in which the flavins move) can be determined according to Eqn. 4 
[35]: 
ßfülzßl = 3 c o s 2 e _I (4) 
ßT + ßsd=v 2 2 
For the dimer form of the scFv aFlo x we determined a centre-to-centre 
distance (R) of 32 Â between the two antigen binding sites at an angle (0) of 
143±1.3°. From the crystal structure of a dimerized antibody with a 5 
residue flexible linker a distance of 65 Â between the antigen binding sites 
has been determined [36]. However, aFlox has a 15 residue (Gly4Ser)3 linker 
and hence there will be less constraint between the two subunits of the 
dimer so that they can approach each other more closely. 
The affinity constants of aFlo x for Flox and Flred were calculated from 
the decrease of the free flavin contribution in the rotational correlation 
times as described in [13] (Table 1). The affinity constants of aFlreci5 for 
Fired (both protonated and deprotonated at N(l)) have been published 
elsewhere [13] but have been included in Table 1 for comparison. 
4.3.3.2. Steady state fluorescence 
We also investigated binding of aFlox to Flox, riboflavin and FMN using 
steady state fluorescence. Fig. 5 shows the quenching of the tryptophan 
(Trp) fluorescence upon titrating with Flox and riboflavin. The titration 
curves shows a striking biphasic pattern that could not be fitted to a 
function describing the hyperbolic curve characteristic for antibody-
antigen binding (see for example [13]). The large initial decrease could not 
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antibody flavin Kd (uM) shift in Eo' (mV) 
aFlox 
aFlred5 
MOX 
Fired 
Rf 
FMN 
Flox 
Fired 
Rf 
43(1,3) 
15,5 (2,3) 
23(1,3) 
43(2,3) 
42(2,3) 
100(2,3) 
4.0(1,4) 
0.6(1,5) 
>100(2,3) 
+8(3) 
+41(4) 
+65(5) 
(1) determined b y time-resolved fluorescence 
(2) determined by ELISA 
(3) determined at p H 7.2 
(4) determined at p H 6.0 
(5) determined at p H 7.5 
Table 4.1. Summary of dissociation constants (Kd) and redox potential 
shifts (AE). 
be due to photobleaching of the Trp since in the absence of flavin and 
under continuous excitation (for 20 minutes) there is only a fast 6% 
decrease in Trp fluorescence followed by stabilization of the Trp emission. 
Moreover, the decrease was not dependent on the light intensity. 
However, it has been known for a long time that flavins can sensitize 
the destructive photooxidation of a large variety of substrates, such as 
amino acids, in the presence of oxygen [37]. The products of flavin 
sensitized photooxidations have not been clearly identified. Our results 
indicate that one or more Trp residues in the ocFl0x binding site are 
sensitive to photooxidation, explaining the large initial fluorescence 
decrease in the titration curve. However, the fact that after the breakpoint 
in the curve the Trp fluorescence still slowly decreases suggests that there 
are also Trp residues involved in binding that are not sensitive to 
photooxidation. The crippled antibody that remains after photooxidation 
is still capable of binding flavin although with a decreased affinity 
(reflected in the flatter part of the titration curve). Flox and riboflavin both 
have the same effect on photooxidation since the titration curves overlap. 
Therefore it is not possible to pronounce upon differences in affinity 
between two flavin analogues. 
The breakpoint in the titration curves is located around 0.5 \xM flavin. 
Since it has been known that part of the purified antibody might be 
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incorrectly folded [38], we assume that this is the concentration of correctly 
folded antibody (we assume that only correctly folded antibody binds 
flavin). This implies that only one Trp residue is close enough to the 
flavin to be photooxidized since this is less than equimolar to the antibody 
concentration (0.7 |iM). From this it can be estimated that 70% of the 
purified scFv has been properly folded. 
We tried to determine the affinity of aFlox for Flrecj using this approach. 
This was, however, not possible since it appeared that dithionite, used to 
reduce flavin, quenches the Trp fluorescence. Furthermore we could not 
study binding of Flox (and other flavin derivatives) to aFl red5 due to the 
weak binding of this scFv to Flox [13]: the amount of flavin that has to be 
added to quench the Trp is so large that flavin will absorb part of the 
excitation light. 
4.3.3.3. Competitive ELISA 
Competitive ELISA experiments with aFlox have been performed using 
Flo x , riboflavin and the well-soluble FMN as competitors. We basically 
followed the method described by Friguet et al [23] except that we did not 
pre-incubate antibody and antigen. In our opinion, this step only is useful 
when the equilibrium between bound and free antibodies is slowly 
attained. Based on knowledge of kon and k0ff rates for antibody-antigen 
binding this is only true for high affinity antibodies (see for example [24]). 
In our experiments the ELISA plate was coated with a BSA-Flox conjugate 
whereas different flavins served as competitive antigens in solution. 
Therefore, the competition is not strictly fair in case riboflavin and FMN 
are used as competitors, since it might be expected that the affinity for Flox 
(coated to the plate) is higher than for these flavin derivatives. Therefore 
the dissociation constants determined must be considered as relative 
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values which can very well be used to rank the strength of binding of 
aFlox to different flavins. 
The results obtained are shown in Table 1 and indicate that the 
substituent on N(10) plays a role in binding: riboflavin and FMN bind 
worse than FlOX/ to which the antibody was selected. Apparently, the extra 
phosphate group that FMN possesses compared to riboflavin does not 
influence binding, neither sterical nor electrostatical. 
Competitive ELISA was also used to study binding of aFl r ed5 to Flo x 
(described in [13]) and riboflavin. In the latter case we could not determine 
the apparent binding constant for riboflavin exactly because the situation 
that antibody binding to the ELISA plate is fully inhibited by the 
competing antigen, could not be reached. Therefore we must conclude 
that binding to riboflavin is at least several orders of magnitude weaker 
than to Flox (Table 1). 
4.3.4. Redox potentials 
The flavin redox potential indicates the tendency of the flavin molecule 
to aquire or donate electrons. The shift in redox potential (AE0 ' ) upon 
binding of antibody to flavin shows how the antibody affects this. AE0' 
values have been calculated for both scFv fragments for the F l o x /F l r e d 
couple from the dissociation constants obtained from time-resolved 
fluorescence data (Table 1). For aFl0X we only observe a minor shift, but 
<xFlred5 causes a +41 to +65 mV shift in E0' dependent on pH. Intuitively, 
these redox potential shifts indicate that aFlox binds more to ring A of the 
flavin or to the N(10) substituent and that aFlred is more directed against 
ring C. 
4.3.5. Modelling of the antigen binding site 
To understand the molecular basis of the regulation of the flavin redox 
potential by the antibody, we took advantage of the highly conserved and 
well-studied structures of antibody V domains and generated models of 
the 3-dimensional structures of the Fv domains of ocFlox and aFlred5, based 
on sequence homology with antibody structures from the Brookhaven 
database. 
A fragment of the three dimensional model of the Flox-aFlox complex is 
shown in figure 6A. Flox is positioned in a cavity in the <xFlox binding site 
that on the bottom side is closed by Trp H47 (±7 Â from ring A of the 
flavin) while another Trp residue, H50, is also much involved in shaping 
the binding site (Trp H47 and H50 are not shown in this model). These 
two Trp residues, however, are not directly involved in binding, in 
contrast to another Trp (H98). Flo x is bound mainly by hydrophobic 
interaction of this residue with ring A of the flavin. The N( l ) /C2=0 part 
of ring C and the main part of the "tail" (except for the terminal carboxyl 
group that points back to the protein) stick out of the antigen binding site 
into the solvent. There is a hydrogen bond between flavin C(4)=0 and the 
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B 
Fig. 4.6. Fragment sof the 3-dimensional models of Flox bound to aFlox (A) and of Fired (depro-
tonated a tN( l ) )bound toaF l i ed5 (drawn with the graphical program O [46]). 
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backbone NH of Tyr L32. Another important factor governing the flavin 
binding is an electrostatic interaction between Arg L91 and the terminal 
carboxyl group of the flavin N(10) substituent (±4 Â). 
Figure 6B shows a fragment of the model of Flred-cxFlred5 in the 
situation that N(l) is negatively charged. Flrecj is well-embedded in the 
antigen binding site. Ring C of the flavin is bound by two hydrogen bonds: 
between flavin C(2)=0 and the backbone NH of Tyr L32 and between 
flavin N(3)H and the backbone C = 0 of Tyr L32. In addition there is a 
hydrogen bond between flavin N(10) and Ser H100B. The N(10) 
substituent of the flavin ("tail") plays an important role in binding since 
the terminal carboxyl group forms a hydrogen bond with Ser L93 and a salt 
bridge with Arg L91 (surprisingly this is the same residue that is involved 
in "tail" binding in <xFlox)- This flexible arginine residue can move from 
the terminal carboxyl group to the negatively charged N(l) which explains 
why negatively charged Flred is bound more strongly than its neutral 
form. 
Analysis of the hypervariable loops involved in binding reveals that 
aFlox uses 4 CDRs (LI, L3, H2 and H3) to bind the flavin. H2 is involved in 
shaping the binding site but not directly in binding the flavin. The binding 
site of aFl r ed5 is predominantly shaped by LI, L3, HI , H2 and H3 and 
residues of LI, L3 and H3 are directly involved in binding. According to 
Wilson and Stanfield [39] the minimum number of CDRs used in binding 
is four and H3 and L3 are always used whereas there is a lack of interaction 
between L2 and smaller antigens or haptens. Here too we see this absence 
of L2 in hapten binding for both our antibodies. 
The light chain is in both cases much involved in binding although the 
binding sites are differently shaped. Surprisingly, Arg L91 and Tyr L32 are 
both used for binding in aFlox as well as in cxFlred5. Since the light chain in 
both antibodies is the same, this illustrates once more that not only the 
primary sequence of the V domain determines the structure of the 
binding site, but that interaction between both domains is of the utmost 
importance [40]. 
4.4. Discussion 
scFv antibody fragments binding different flavin forms (aFlo x and 
aFlredS) have been selected from a phage antibody library and are 
characterized by experimental mapping and molecular modelling in order 
to study how a protein regulates the redox potential, but here we use a 
protein other than natural occurring flavoenzymes. Modelling of the 
antigen binding site is a good alternative to understand the molecular 
basis of protein-ligand interactions when no X-ray crystallographic or 
NMR structure is available. The system we investigated lends itself very 
well to this approach since the flavin ligands docked in the antigen 
binding site are relatively rigid (compared to peptide and protein antigens) 
and, in particular, since the result of the modelling can be verified with 
experimental data. 
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4.4.1. Comparison of data obtained by experimental mapping methods 
Binding of aFl0X to Flox was investigated by competitive ELISA and both 
steady-state and time-resolved fluorescence spectroscopy. The latter 
technique is, due to its sensitivity, the preferred method to quantify 
binding to the oxygen sensitive, colourless and low-fluorescent Flred [12]. 
The dissociation constant for Flo x determined from time-resolved 
fluorescence anisotropy data differs from that determined by competitive 
ELISA that is about three fold lower. 
This difference might originate from the fact that the equilibrium 
between antibody and antigen in solution, in the ELISA plate is affected by 
the antigen coated on the surface of the plate. This antigen withdrawes 
part of the antibody from the solution. This might be amplified by the fact 
that Flox tends to dimerize so that not only affinity but also avidity plays a 
role in binding to the flavin coated to the ELISA plate, resulting in a 
stronger binding to surface coated antigen than to antigen in solution. 
This implies that less antigen is needed to satisfy the antibody left in 
solution, resulting in a lower dissociation constant. 
Comparison of steady state fluorescence spectroscopy data, based on 
quenching of the Trp fluorescence by Flox binding, to data obtained by 
time-resolved fluorescence and competitive ELISA is impossible due to 
the interference of photooxidation of Trp in the former experiment. 
However, it is clear that the affinity constant of aFlox for Flox is low (in the 
10'5 M range) and data obtained by the same method can be compared to 
each other. For this reason, the redox potential for the Fl0x/Fl red couple 
was calculated from the dissociation constants obtained from time-
resolved fluorescence anisotropy results. 
aFl0X binds Flox and Flred approximately equally well indicating that 
either ring A of the flavin nucleus or the N(10) substituent is involved in 
binding, since these parts are the same for both Flox and Flred (in contrast 
to ring C that accepts the electrons and adopts a new electron density 
distribution upon reduction). Competitive ELISA experiments with Flox , 
riboflavin and FMN, flavin analogues that only differ in their N(10) 
substituent, reveal that binding to this substituent indeed plays a role 
(Table 1). 
oeFlred binds significantly better to Flred than to Flox as determined by 
time-resolved fluorescence spectroscopy [13], suggesting that ring C of the 
flavin is involved in binding. This is supported by the fact that the affinity 
for Fired is higher when N(l), located in ring C, is deprotonated [13], Since 
riboflavin binds worse than Flox (Table 1), binding to the N(10) substituent 
must also play a role. 
These experimental data give a first outline of the way flavin is bound 
to aFl o x and aFl r ed5 and serve as a basis to judge the validity of the 3-
dimensional molecular models. 
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4.4.2. Validity of the models 
The 3-dimensional model of the aFlox binding site is in good agreement 
with the experimental results. The interaction between ring A of the 
flavin and Trp H98 is the main interaction causing-binding of <xFlox to Flox 
or Flrecj which is in agreement with experimental data. This Trp residue is 
most likely the residue sensitive to photooxidation which fits in our 
assumption that only one Trp residue is involved in photooxidation, as 
determined from the breakpoint in the titration curve monitoring the 
quenching of the Trp fluorescence (Fig. 5). From the slower decreasing 
second part of this titration curve we concluded that there are also other 
Trp residues involved in binding that are not sensitive to photooxidation 
but quench the Trp fluorescence via radiationless energy transfer. We 
assume that Trp H47 and H50 are the residues involved in this process; 
they are probably too remote or not well-positioned for photooxidation. 
When flavin is excited (as in time-resolved fluorescence experiments) we 
noticed quenching of the flavin fluorescence which might be ascribed to 
Trp H98 as well as H47 and H50, or partly to the hydrogen bond between 
flavin C(4)=0 and Tyr L32 [31]. 
The electrostatic interaction between the negatively charged carboxyl 
group at the terminus of the flavin N(10) substituent and the positively 
charged Arg L91 explains the lower affinity for FMN and riboflavin 
compared to Flox . The presence of this Arg residue is unexpected since 
there was no negative charge present in the N(10) substituent of the 
original hapten (instead of the carboxyl group there was a peptide bond 
linking the hapten to a protein carrier). 
The model reveals that the N(10) substituent is exposed to the solvent 
which explains why riboflavin and FMN are bound equally well. The 
terminal phosphate group of the N(10) substituent of FMN can apparently 
not form a salt bridge with Arg L91, probably due to torsion or sterical 
effects (the distance between N(10)-phosphate in FMN is larger than that 
of N(10)-COO" in Flox, moreover a phosphate group is more bulky than a 
carboxyl group). Considering this model the low affinity of aFlox for Flox is 
not surprising, since there are few amino acid residues (only Trp H98, Arg 
L91 and Tyr L32) directly involved in binding and the flavin is not well-
embedded in the antigen binding site. 
The 3-dimensional model of ccFlred5 is also in good agreement with the 
experimental results. As in aFl0 X the flavin is partly bound via the 
carboxyl group at the terminus of the N(10) substituent by electrostatic 
interaction with Arg L91 and also by a hydrogen bond to Ser L93 which 
explains that Flox is bound better than riboflavin. Surprisingly, this 
positively charged Arg residue is flexible enough to move to N(l) of the 
flavin ring when this atom acquires a negative charge. This is obviously 
the explanation for the difference in binding between protonated and 
deprotonated Flred (changes in conformation cannot be the cause here, for 
the geometry of Flred in both ionization states is not greatly different [41]). 
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The arginine shift is undoubtedly a matter of induced fit since aFlred5 was 
selected against protonated Flred-
Furthermore the isoalloxazine nucleus itself is bound by three 
hydrogen bonds: between flavin N(10) and Ser H100B, C(2)=0 and Tyr L32, 
N(3)H and Tyr L32. These hydrogen bonds (in particular the one to N(10) 
[42]) and the constraint the binding pocket imposes on Flred explain the 
increased fluorescence upon antibody binding because the rapid 
interconversions of the multiple, non-planar conformations of reduced 
flavin are damped [30,31]. 
4.4.3. Comparison with other flavoproteins 
CXFIQX hardly influences the flavin redox potential. From previous 
studies (see introduction) it has been known that binding to the redox 
active ring C of the flavin ring predominantly regulates the redox 
potential. Here we have shown that the antibody aFl o x , b i n d i n g 
predominantly to ring A, barely changes the redox potential. The small 
change in redox potential (+ 8 mV) might be due to a polarizing effect Trp 
H98 has on ring A of the flavin [10]. Ring C of the flavin is mainly exposed 
to the solvent which makes aFlo x a "reversed flavodoxin". In flavodoxin 
the flavin, FMN, is also situated on a scaffold of loops as in the antigen 
binding site of an antibody. However, in this case ring A of the flavin 
sticks out to the solvent instead of ring C . 
Positively charged residues in the vicinity of ring C are found to 
increase the flavin redox potential in flavoproteins [6-8]. For flavodoxin it 
has been explicitly suggested that in particular the interaction with the 
flavin N(l) nucleus is important for the regulation of the redox potential 
[43]; the unfavorable electrostatic interaction between the phosphate 
dianion and the negatively charged flavohydroquinone has been proposed 
as a partial explanation for the low redox potential of flavodoxins [44]. For 
oxidases it has been shown that positively charged residues in the vicinity 
of N(l) contribute to increase the redox potential (see introduction). Our 
model indicates that aFl r ed5 has a positively charged arginine residue 
(L91) that not only shields the negatively charged carboxyl group at the 
end of the N(10) substituent of Flred, but also interacts with N(l) when 
deprotonated. We assume that these interactions are mainly responsible 
for the 65 mV increase in the redox potential when aFl r ed5 binds to 
deprotonated Flred. When Flred is protonated at N(l), there is a smaller, 
+41 mV, shift in redox potential, that we ascribe mainly to the favorable 
electrostatic interaction between the carboxyl group and Arg L91. 
The hydrogen bonds to flavin N(10), C(2)=0 and N(3)H probably also 
contribute to the positive shift in redox potential by increasing the 
activation barrier for the transition from the bent to the planar 
conformation [42]. 
In the future these models needs to be further verified by mutagenesis 
studies. This will be a comprehensive study since the redox potential is 
not only regulated by amino acids having a close contact with the flavin, 
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but also by charged residues at a greater distance of the flavin nucleus [9]. 
In the present study of our models we only judged those residues that 
were in immediate contact with the flavin. 
4.5. Conclusion 
Our approach using non-natural flavin binding proteins to investigate 
the way a protein environment regulates the flavin redox potential 
supports observations on natural flavoproteins. These flavin binding 
antibodies ("flavobodies") form tailored protein environments that can be 
generated against any flavin of interest within a period of a few weeks, 
even if they are not stable under physiological conditions [13]. ocFlred5 
shows an "oxidase like" redox potential behaviour confirming the idea 
that positively charged residues in the vicinity of N(l) increase the redox 
potential. Furthermore this antibody indeed shows that interaction with 
the flavin N(l) directly influences the redox potential. However, the 
flavobody aFlox is the most remarkable result of this approach: this flavin 
binding antibody, that does not resemble a natural flavoprotein, shows 
that when ring C of the flavin is not involved in binding, the redox 
potential in turn is not significantly affected. 
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Accelerated oxidation of dihydroflavoquinone by a flavin-binding 
antibody* 
5.1. Introduction 
To date antibodies have been reported to catalyze a wide variety of 
chemical reactions, including redox reactions (for a review see [1]). 
However, in these antibodies the oxidat ion/reduct ion is directly 
performed by highly reactive compounds (such as hydrogen peroxide, 
sodium periodate or sodium borohydride) without the assistance of redox 
active groups in the antibody. Shokat et al [2] have shown that a reduced 
flavin-antibody complex was a more powerful reductant than free reduced 
flavin due to a shift to a more negative flavin redox potential upon 
antibody binding. The flavin, however, was not catalytically reduced in 
the antigen binding site. The goal of this work is to develop an antibody 
that can recycle a cofactor in its antigen binding site. As a first step we 
investigated the oxidation of reduced flavin in an antigen binding site. 
Additionally, we attempted to catalytically reduce the flavin in the antigen 
binding site. 
Reduced flavin is very reactive towards molecular oxygen (02). The 
initial reaction probably proceeds by a one-electron reduction of 0 2 (to 
superoxide) followed by a radical recombination reaction yielding the 
C(4a)-hydroperoxy-4a,5-dihydroflavin as an intermediate, which in turn 
disintegrates by either a homolytic or a heterolytic reaction of the C(4a)-
OOH bond [3]. Flavoprotein oxidases and monooxygenases accelerate the 
oxidation of reduced flavin by a factor 100-1000 [4] suggesting stabilization 
of the hydroperoxide, for example by hydrogen bonds from the flavin 
N(5)H or the peroxide to amino acids, or by creating a hydrophobic 
environment for the flavin hydroperoxide [5]. 
5.2. Experimental procedures 
5.2.1. Oxidation of antibody-bound reduced flavin 
To investigate the influence of reduced flavin binding antibodies on the 
reoxidation rate of reduced flavin, we studied the production of 
superoxide (02~) which is formed by a one electron transfer from reduced 
flavin to 02 . 02~ is captured by nitro blue tetrazolium (NBT) to form blue 
formazan. 1 i^M riboflavin (from Sigma) (for aRfmodG!) or N(10)-5'-
carboxybutyl-flavin (for ocFlred5), 10 mM EDTA, 20 mM NBT (from 
Part of this chapter will be published as extended abstract in de Proceedings of the 12th 
Internat ional Sympos ium on Flavins and Flavoproteins (Calgary, 1996) (Y.E. 
Bruggeman, W.R. Mulder, A.J.W.G. Visser, N.C.M. Laane, A. Schots and R. Hilhorst) 
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Boehringer Mannheim) and various antibody concentrations in air-
saturated buffer were illuminated with white light to reduce the flavin [6] 
during several time intervals of 2 minutes. After each period of light 
exposure, blue formazan was detected at its absorption maximum (e560 = 
10,4 mM-'cnr1, [7]). Antibody concentrations were chosen so that the 
percentage of bound reduced flavin varied from 0 to nearly 100%. At room 
temperature, experiments with aRfmodGi were performed in 50 mM 
phosphate/150 mM NaCl pH 7.0, whereas experiments with <xFlred5 were 
performed in 100 mM phosphate/100 mM NaCl pH 7.5. 
5.2.2. Reduction of antibody-bound oxidized flavin 
To investigate the reduction of antibody bound flavin by NAD(P)H, 1 
^M riboflavin was incubated with 50nM NAD(P)H (from Boehringer 
Mannheim) and 3 jiM aRfmodG! (sites) (more than 90% of the flavin is 
bound under these conditions) in PBS. To prevent reoxidation of reduced 
flavin, the solutions were deaerated by flushing with argon. Traces of 
oxygen were removed by adding 2 nM glucose oxidase (Boehringer 
Mannheim) and 0.1 mM glucose. Reduction of the flavin was followed, 
after excitation at 450 nm, on a SPF 500C Spectrofluorometer (SLM 
Aminco) at its emission maximum (525 nm). 
To investigate the reduction of antibody bound flavin by benzoyl formic 
acid (see Fig.l, chapter 2), the experiment was set up as described under 
5.2.1 with the exception that NBT was replaced by 10 mM benzoyl formic 
acid (from Aldrich). 
5.3. Results and discussion 
5.3.1. Reoxidation of flavin in the antigen binding site (cofactor recycling) 
Starting-point to investigate the capability of antibodies in catalyzing 
cofactor recycling (reoxidation of reduced flavin in the antigen binding 
site) is the reactivity of reduced flavin with 0 2 . Monoclonal antibodies 
have been generated against reduced flavin: aRfmodG! (against the hapten 
N(5)-benzoyl-N(10)-(ribityl succinamide ester) flavin [8]) and aFlred5 
(against l,5-dihydro-N(10)-5'-carboxybutyl flavin [9]) (see Fig. 5.1). aRfmodGi 
is a complete antibody (IgG! isotype) obtained via mouse immunization. 
On the contrary <xFlred5 is a single chain Fv antibody fragment [10], 
composed of the two antigen-binding domains connected by a peptide 
linker, generated entirely in vitro by antibody phage display technology. 
Binding of these antibodies to oxidized and reduced flavin was 
characterized by time-resolved fluorescence [8,9]: affinities of ccR^cG] and 
otFlred5 for reduced flavin are 0.07 and 0.6 |iM and for oxidized flavin 6 and 
100 jiM, respectively. 
To determine whether the protein environment of these antibodies can 
accelerate the oxidation of reduced flavin by 02 , superoxide (Gy), formed 
by electron transfer from reduced flavin to 02 , was trapped with nitro blue 
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Fig. 5.1. Haptens for the antibodies ocRfm0(jGi (A) and otFlrecj5 (B). 
tetrazolium (NBT) resulting in the formation of blue formazan. For 
«RfmodGi, the 02~ production rate (v) steeply increases at low antibody 
concentrations (Fig. 5.2A). However, at higher concentrations, the 02~ 
production rate gradually declines. This suggests two competing processes: 
on the one hand antibody-bound reduced flavin is reoxidized faster than 
free reduced flavin, but on the other hand antibody-bound oxidized flavin 
can not be reduced by EDTA and light any more and is therefore 
withdrawn from the reaction mixture (Fig. 5.3). Indeed, in an experiment 
in which all flavin was bound to antibody in a fully anaerobic 
environment, the antibody-flavin complex could not be reduced as 
monitored by steady-state fluorescence. This is feasible because flavin and 
EDTA have to form an adduct to achieve reduction of the flavin [6]. 
Apparently antibody-bound flavin is not accessible for EDTA as is the case 
for many flavoproteins [6]. The acceleration factor (kbound/kfree) f ° r 
oxidation of antibody-bound reduced flavin compared to free reduced 
flavin was determined from: 
v= kfree * Flfree + kbound * Flbound 
where v is the superoxide production rate (in nmol.min'l), kbound a n d 
kfree are rate constants (min'l) and Flfree and Flbound a r e the amounts of 
free and antibody-bound reduced flavin present in solution (in nmol). 
The acceleration factor was determined for those points where the fraction 
bound oxidized flavin could be neglected, allowing determination of the 
amounts of free and bound reduced flavin from the dissociation constant 
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Fig. 5.2. Effect of reduced flavin binding antibodies on the rate of O2" production for 
1 nmol flavin . A, ocRfmodGi ; B: aFlred5. 
of ocRfmodG! for reduced flavin. We found that oxidation of ocRfmodGi bound 
flavin is 12 times faster than that of free reduced flavin. 
Figure 5.2B, showing the effect of aFlred5, reveals a different curve: the 
02" production rate is independent of the antibody concentration. Within 
this antibody concentration range we should have noticed an eventual 
acceleration and, given the Kd of aFlred5 for oxidized flavin (100 nM), 
withdrawal of oxidized flavin does not play a role here. The acceleration 
of 02~ production rate was aRfmodG! specific, since an aspecific antibody 
(aBSA) did not show an effect on the 02" production rate in the range 
where ccRf^G! showed a sharp increase. 
Since the reaction rate strongly depends on the oxygen concentration if 
this is > 0.2 mM [3], small differences in temperature and atmospheric 
conditions influence the reaction rate considerably. This most likely is the 
explanation for the higher rate of 02~ production in absence of antibody in 
Fig. 5.2A (compared to 2B) rather than small differences in pH or N(10) 
substituent of the flavin. N(10)-5'-carboxybutyl flavin (Fig. 5.2B) shows a 
two times higher 02~ production compared to riboflavin. 
The shift in redox potential (AE) upon binding of the flavin to the 
antibody reflects the flavin redox state stabilized by the antibody. AE values 
for two-electron transfer were calculated based on thermodynamic criteria 
[11] (see also Chapter 4) from the dissociation constants for oxidized and 
reduced flavin [8,9]. Both antibodies stabilize the flavohydroquinone: +56 
mV and +65 mV shifts were determined, due to binding to aRfmodG! and 
aFlred5, respectively. 
The antibody aRfmodGi accelerates the 02" production rate 12 times. This 
is not the result of the redox potential shift since aFlred5, that causes a 
comparable shift, does not influence the 02~ product ion rate. 
Consequently, the rate acceleration must be due to the protein 
environment; this could either be an apolar pocket around N(5) or 
hydrogen bonds to N(5) or the hydroperoxide that stabilize the C4a-
hydroperoxydihydroflavin and were induced by the N(5) benzoyl 
substituent in the hapten. This hypothesis is supported by the fact that the 
antibody aFl red5, generated against 1,5-dihydroflavoquinone, hardly 
showed an effect on the 02~ production rate. The latter is in agreement 
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Fig. 5.3. Reaction scheme. 
with the 3-dimensional model of the antigen binding site of ceFlred5 (see 
Chapter 4). From this model it is clear that there are no hydrogen bonds to 
the flavin N(5) or C(4a), neither are there hydrophobic residues in the 
vicinity of these two atoms. 
The rate acceleration found for oRf^jG! is 10-100 fold lower than for 
most oxidases. This could be related to the flavin conformation, i.e. planar 
versus bent. For example, in flavodoxins flavohydroquinone is forced into 
a planar conformation which probably makes it a more powerful reducing 
agent. In most oxidases the flavo-hydroquinone is also held in a flat 
conformation. Antibodies, however, are adapted to the conformation the 
flavin possesses d u r i n g an t ibody selection. Therefore the 
flavohydroquinone must be in the bent conformation when bound to 
«RfmodG! or aFl r ed5. 
5.3.2. Reduction of antibody-bound flavin 
Now that we have proven that aRfmodGi can accelerate the oxidation of 
reduced flavin, we have tried to reduce flavin specifically in the antigen 
binding site. However, flavin could not be reduced in the antigen binding 
site in the presence of benzoyl formic acid and light, NADH or NADPH. 
5.4. Conclusion 
Here, we have shown that antibodies are able to accelerate oxidation of 
reduced flavin within the antigen binding site. Comparison of two 
antibodies that bring about a comparable shift in redox potential, indicates 
that the reoxidation rate of reduced flavin is not dependent on the redox 
potential. However, the flavin could not be catalytically reduced in the 
antigen binding site. Therefore we must conclude that at present this 
flavobody cannot accomplish a catalytic redox cycle. On the one hand, 
screening more substrates might yield a compound that can reduce 
antibody bound flavin and so complete the cycle. On the other hand, it 
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might be wiser to do a step backwards and to redesign the hapten. 
Modulation of the flavin conformation via hapten design could yield a 
next generation of more efficient flavobodies and shed more light on the 
role of flavin conformation and redox potential in catalysis. 
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Summarizing discussion 
6.1. Introduction 
Nature provides a pool of thousands of different enzymes. These 
highly evolved catalysts selectively accelerate chemical reactions. Natural 
biocatalysts, however, are often not stable under the more extreme 
conditions under which chemical processes are performed, such as high 
temperature or pH. Moreover, there are many reactions for which no 
natural enzyme is known. Therefore, the development of artificial 
enzymes has been given serious attention the last decade. 
These artificial enzymes can be divided in three categories: synzymes, 
molecular imprinted polymers (MIPs) and catalytic antibodies (or 
abzymes). The first category comprises supramolecular systems such as 
cyclodextrines and porphyrins that are designed to form a substrate-
binding pocket containing catalytically active groups. The second category 
consists of polymers formed in the presence of a target molecule that 
resembles a transition state of a reaction and acts as a template for 
polymerization; upon removal of the template, a specific cavity is created. 
The third category, catalytic antibodies, has been extensively described in 
1.3 of this thesis. Compared to natural enzymes, that accelerate reactions 
up to 1017 fold [1], artificial enzymes are slow. Catalytic antibodies are 
generally more efficient than synzymes or MIPs; the best catalytic 
antibodies give rate accelerations of 106 fold whereas synzymes at their best 
give 103-104 fold accelerations and MIPs are even slower with 10-100 fold 
rate enhancements [2,3]. Thus catalytic antibodies are at present the best 
artificial enzyme system, which is not surprising since catalytic antibodies 
use the same building blocks as enzymes (i.e. amino acids). These highly 
versatile building blocks differ in size, shape, charge, polarity and chemical 
reactivity and thus form a reservoir of chemical reactivity that can be 
applied to build tailored biocatalysts. Moreover, catalytic antibodies are, 
compared to the other artificial enzymes, relatively easy to generate and to 
modify. 
For these reasons, we chose the catalytic antibody system to attain our 
goal: the development of an artificial enzyme mimicking a redox enzyme 
(discussed below). 
6.2. Design and development of a redox-active catalytic antibody 
To extend antibody catalysis to cofactor-dependent redox reactions, we 
chose to mimic flavoprotein oxidases. To achieve this goal the antibody 
must bind flavin ("flavobody") and thus be elicited against a flavin 
(analogue). We designed a flavin-based hapten, that served a threefold 
goal. Firstly, it should be in a reduced flavin conformation since in 
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oxidases the flavin cofactor is reduced upon substrate oxidation. Secondly, 
it should also introduce a substrate binding pocket in the antigen binding 
site. Thirdly, it must introduce a hydrophobic pocket adjacent to N(5) or 
hydrogen bonds to the N(5) or the C4a position of the flavin, since this 
will facilitate reoxidation of the flavin in the antigen binding site. The 
hapten N(5)-benzoyl-N(10)-(ribityl succinimide) ester flavin seems to 
serve this threefold goal. The N(5) substituent both stabilizes the reduced 
conformation of the flavin (since 1,5-dihydro reduced flavin is not stable) 
and will induce a hydrophobic pocket adjacent to N(5) that could both 
serve as a substrate binding pocket and facilitate reoxidation of the flavin. 
The antibody (xRfmodGi, generated against this hapten, using traditional 
hybridoma technology (see 1.4.1), stabilizes the reduced flavin 
conformation as was proven by time-resolved polarized fluorescence 
binding studies with oxidized and reduced flavin (Chapter 2). A +56 mV 
shift in redox potential compared to free flavin (AE0') for the two-electron 
reduction, was calculated from the dissociation constants for reduced and 
oxidized flavin (0.07 and 6 \iM, respectively). ocRfmodGi accelerates the 
reoxidation of reduced flavin 12 times, which is only 10-100 times less 
than for most oxidases (chapter 5). We ascribed this difference with 
oxidases to the flavin conformation, i.e. planar versus bent. For example, 
in flavodoxins flavohydroquinone is forced into an energetically less 
favorable planar conformation which probably makes it a more powerful 
reducing agent. In most oxidases the flavohydroquinone is also held in a 
flat conformation. Antibodies, however, are adapted to the conformation 
the flavin possesses dur ing antibody selection. Therefore the 
flavohydroquinone must be in the bent conformation when bound to 
aRfmodG!. 
In contrast, the scFv antibody fragment ocFlred5, elicited via an 
alternative strategy against (reduced) 1,5-dihydroflavin (Chapter 3), did not 
show an effect on the reoxidation rate of reduced flavin. This antibody 
causes a comparable shift in E0'. Consequently, the rate acceleration must 
be due to the specific protein environment induced by the N(5) benzoyl 
substituent in the hapten. 
Unfortunately, ocRfmodGi bound flavin could not be reduced by NADH, 
NAD(P)H or benzoyl formic acid. Therefore we must conclude that at 
present this flavobody cannot accomplish a catalytic redox cycle. On the 
one hand, screening more substrates might yield a compound that can 
reduce antibody bound flavin and so complete the cycle. On the other 
hand, it might be wiser to do a step backward and to redesign the hapten. 
For example, a C(5) substituted 5-deazaflavin will have the advantage of a 
flat conformation which will probably enhance the flavin reoxidation rate. 
Moreover, the N(5) substituent should be more carefully designed with a 
direct relation to the substrate to be used and preferentially possess some 
features of the transition state conformation of the substrate (for example 
a imine like N(5) substituent to mimic alanine oxidation). 
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6.3. Antibodies against an unstable hapten 
Antibody technology has made a great stride forward since the 
development of hybridoma technology in 1975 [4]. The possibility to 
display functional antibody fragments at the tip of filamentous phage has 
allowed the development of antibody phage libraries. At present 
antibodies can be generated totally in vitro from naive (i.e. derived from 
an unimmunized source) phage display libraries [5]. With this technique 
animal cell culture and even mouse immunization are by-passed. 
Moreover, we demonstrated that antibodies can even be generated against 
the unstable hapten 1,5-dihydroflavin. This reduced flavin rapidly 
reoxidizes under aerobic conditions and can therefore not be used directly 
for the generation of antibodies in (the aerobic environment of) a mouse. 
However, using a naive antibody scFv phage display library, we could 
perform the selection under anaerobic and reducing conditions and were 
able to select an antibody, aFl red5, that specifically binds 1,5 dihydro-
reduced flavin (Chapter 3). 
6.4. Regulation of the flavin redox potential by flavobodies 
The role of the protein environment of the flavin cofactor in 
modulating its redox potential is still not thoroughly understood. Up till 
now the most comprehensive studies have been performed on 
flavodoxins, but other flavoproteins such as D-amino acid oxidase have 
been investigated too in this respect, although not as thoroughly [6]. In 
order to contribute to a better understanding of this issue, we have 
generated scFv antibody fragments against reduced (see chapter 3) and 
oxidized flavin (see chapter 4). These flavobodies are characterized by 
time-resolved and steady-state fluorescence spectroscopy and ELISA 
methods (mapping) and molecular modelling. The 3-dimensional models 
of the antigen binding sites were in good agreement with the 
experimental results. Binding of aFl r ed5 to flavin increases the redox 
potential, mainly due to an arginine residue interacting with the flavin 
N(l). This was in agreement with literature data on oxidases claiming that 
positive residues in the vicinity of ring C of the flavin (see fig. 1.2, chapter 
1) increase the flavin redox potential. However, the flavobody aFlox is the 
most remarkable result of this approach: this flavin binding antibody, that 
does not resemble a natural flavoprotein, shows that when the electron 
deficient ring C of the flavin is not involved in binding, the redox 
potential is not significantly affected (chapter 4). 
In conclusion, we like to state that flavobodies form tailored protein 
environments that can be selected from antibody phage display libraries 
against different flavin analogues, even if they are not stable under 
physiological conditions, within a period of a few weeks. For these 
reasons, antibody fragments are novel tools, additional to natural 
proteins, to study the effect of different protein environments on the 
flavin redox potential. Moreover, when expressed in E.coli, primary 
89 
Chapter 6 
sequence information can easily be obtained and mutations can readily be 
performed which could give additional information on the effect of a 
specific amino acid on the flavin redox potential. 
6.5. The future of redox-active flavobodies 
We have shown that it is possible to generate antibodies that influence 
the flavin redox potential, even in a fashion comparable with natural 
flavoproteins (chapter 4). We have also shown that antibodies are capable 
of catalyzing the reoxidation of reduced flavin, like oxidases (Chapter 5). 
However, we failed to develop an antibody that catalyzes flavin reduction 
by substrate binding. The results described here taught us that the 
development of a redox active flavobody is an ambitious project. First of 
all a better hapten should be designed (and synthesized) that will lead to 
an antibody that can bind both the flavin cofactor and the substrate in the 
correct conformation and orientation. Moreover, it should induce those 
amino acids that regulate the flavin redox potential in the desired way 
(based on current knowledge) and which activate the substrate when 
placed in the antigen binding site. 
The second step is the generation of antibodies against such a hapten. 
This can be performed either in vivo or in vitro. In vitro strategies have 
the advantage that the hapten does not necessarily have to be stable under 
physiological conditions (Chapter 3). Moreover, different elution strategies 
can be applied in the panning procedure as described in Chapter 3. Here, 
our goal was to select antibodies specific for reduced flavin. In order to 
remove cross-reactive antibodies (i.e. antibodies that also bind oxidized 
flavin), we performed a pre-elution step with oxididized flavin prior to 
eluting the (specific) reduced flavin binding antibodies with reduced 
flavin. This strategy yielded an antibody population enriched for reduced 
flavin binding. This approach might be extended, for example, if one 
wants to select for antibodies binding ring C of the flavin. In that case pre-
elution with a flavin analogue substituted on ring C (thus eluting ring A 
binders) might be useful. On the other hand, with in vitro selection of 
antibodies from naive antibody phage display libraries, the chance of 
success is dependent on the library size and diversity: large and diverse 
libraries give a higher chance of selecting antibodies with the desired 
properties (here we used a library with a repertoire size of 108, at present, 
however, repertoires of >1010 are available). 
These improved selection strategies, however, are related to selection 
for binding and not for catalysis. For this much more powerful selection 
strategies are required. For enzymes a very elegant selection strategy, based 
on phage display (see 1.4.3), has been developed to select for catalytic 
activity [7]. In this approach enzymes displayed on phage are selected by 
their catalytic activity using a suicide inhibitor linked to a biotin. Active 
phage enzymes were covalently attached to the suicide inhibitor and could 
be captured with streptavidin-coated beads. For flavoenzymes suicide 
inhibitors have been reported [8] that inactivate D-amino acid oxidase via 
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modification of an active site histidine. Using such an inhibitor, one can 
select for the presence of a histidine in the antigen binding site. If, based 
on such inhibitors, a selection system for redox active flavobodies could be 
developed, this would greatly enhance the chances of selecting a catalytic 
antibody. The best strategy would be first to select a large and diverse 
repertoire of phage antibodies against an optimally designed hapten, and 
then to randomly mutate these first generation flavobodies and select 
them for covalent binding to suicide inhibitors. 
6.6. Conclusion: the future of catalytic antibodies in general 
Although scientists have been quite successful in developing catalytic 
antibodies for a wide variety of chemical reactions, most catalytic 
antibodies are modest catalysts at best. This is not surprising since the 
evolution of enzymes has been going on for millions of years whereas 
catalytic antibodies are only in the first stage of their "evolution". During 
their evolution enzymes have been taught not only to bind selectively the 
transition states of their substrates but also to participate directly in bond 
making and breaking. Most catalytic antibodies only have been selected for 
binding a transition state analogue, although a few strategies for direct 
selection for catalysis. The principle of this approach is that a catalytic 
antibody is expressed in bacteria lacking an enzyme that is crucial to 
survive; only those bacteria that express a catalytic antibody that catalyzes 
the same reaction as the missing enzyme will survive. Improving 
catalysis by mutagenesis ("evolution") has been described (for example [9]). 
One of the problems in selecting catalytic antibodies is to "fish" a weak 
antibody catalyst out of a pool of enzymes simultaneously produced by the 
hybridoma or bacterial cell. An enzyme contamination of less than 0.1% 
in the purified antibody sample can catalyze substrate conversion and 
insinuate that it is the antibody that is catalytically active. We have been 
working on a catalytic antibody, elicited against the hapten N(5)-benzoyl-
N(10)-(ribityl succinimide) ester flavin, that seems to show 
phosphodiesterase activity to several carbohydrate-phosphate esters. In a 
way this is not surprising since these antibodies bind carbohydrates due to 
the carbohydrate substituent at the N(10) of the flavin hapten. However, 
we found that the hybridoma cells producing this antibody also produce 
several phosphodiesterases that could stick to the antibody during the 
purification steps and confuse the measurements for catalytic activity. 
It remains to be seen if it is worth the effort to develop catalytic 
antibodies for reactions for which there are also enzyme equivalents. In 
this case the only benefit could be that the process of designing and 
developing these antibodies teaches us more about how enzymes work [2]. 
However, there are other cases where catalytic antibodies, despite the 
efforts it costs to construct them, may be useful: for synthesis of 
compounds for which no enzyme alternative exists (for example [10,11]) 
and for prodrug activation used in therapy [12,13]. In the latter case the 
present situation is that enzymes are linked to antibodies recognizing 
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tumor epitopes; the enzymes activate prodrugs for efficient tumor killing. 
The problem is that most enzymes are of non-human origin and therefore 
give rise to an immune response of the patient against the enzyme. 
Humanized catalytic antibodies may replace these enzymes and thus 
circumvent this problem. In conclusion, there are practical applications 
for catalytic antibodies that are worth the efforts and costs to generate 
them. In other cases the scientific challenge is to learn more about 
enzymes by mimicking their evolution in an (relatively) extremely short 
period of time (i.e. decades). 
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Abbreviations 
BSA bovine serum albumine 
CDR complementarity determining region 
ELISA enzyme-linked immunosorbent assay 
Fat, a light chain dimerized to VH-CH1 
FMN flavin mononucleotide 
Flox N(10)-5'-carboxybutyl-flavin (see chapter 3) 
Flred N(10)-5'-carboxybutyl-l,5-dihydroflavin (see chapter 3) 
FR region framework region 
MEM maximum entropy method 
MIP Molecular Imprinted Polymer 
PBS phosphate-buffered saline 
scFv single chain Fv fragment 
V domain antibody variable domain 
ocFlox scFv against N(10)-5'-carboxybutyl-flavin 
aFlred scFv against N(10)-5'-carboxybutyl-l,5-dihydroflavin 
aRfmodG! IgGî against the modified riboflavin 3a (see chapter 2) 
aRfmodM IgM against the modified riboflavin 3a (see chapter 2) 
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Samenvatting voor niet-vakgenoten 
In ons dagelijks leven spelen enzymen een vitale rol. Enzymen zijn 
eiwitten die in staat zijn chemische reakties selectief en veelal meer dan 
een miljard keer te versnellen. In ons lichaam verlopen bijna alle 
processen met behulp van enzymen. Kenmerkend voor enzymen is dat ze 
in het algemeen onder milde reaktiecondities werken en minder 
ongewenste bijprodukten geven dan "klassieke" chemische processen. 
Vanwege deze redenen is ook de industrie in toenemende mate 
geïnteresseerd in het gebruik van deze "schone" biokatalysatoren. Een 
bekend voorbeeld zijn de proteases (eiwit splitsende enzymen) en lipases 
(vetsplitsende enzymen) in wasmiddelen die eiwit- en vetvlekken uit 
textiel kunnen verwijderen. Een ander voorbeeld is het gebruik van het 
pectinase om de helderheid van vruchtesappen en wijn te verbeteren. 
Enzymen hebben echter als nadeel dat de milde reaktiecondities 
waaronder ze werken soms ook ongunstig kunnen zijn: als het enzym 
traag werkt onder de gegeven condities, kan dit bijna niet verbeterd 
worden door bv. de temperatuur te verhogen of de pH (zuurgraad) te 
veranderen, omdat dit vaak invloed heeft op de stabiliteit van het enzym. 
Bovendien zijn er ook tal van reakties te bedenken waarvoor geen 
natuurlijk voorkomend enzym beschikbaar is. Dit heeft de laatste jaren 
geleid tot een toenemende interesse in het ontwikkelen van artificiële 
enzymen (ook wel synzymen genoemd), die de bestaande verzameling 
van natuurlijke enzymen moeten uitbreiden. 
Een inmiddels beroemde klasse van artificiële enzymen zijn de 
katalytische antilichamen (ook wel abzymen genoemd), die het 
onderwerp van dit proefschrift zijn. Om te begrijpen hoe deze katalytische 
antilichamen werken, moet we eerst wat meer in detail kijken naar hun 
natuurlijke tegenhangers, de enzymen. In een enzym vindt de reaktie 
plaats in een holte van het eiwitmolekuul, het actieve centrum. Hier 
worden de substraten (= stoffen die door het enzym omgezet worden) 
gebonden en zijn katalytische groepen aanwezig die ervoor zorgen dat de 
reaktie verloopt. De katalytische groepen in het actieve centrum zijn 
zodanig gerangschikt, dat selectief een bepaalde groep van het substraat 
wordt omgezet. 
Het principe van katalytische antilichamen is nu dat in het antilichaam 
het actieve centrum van een enzym nagebootst wordt. Antilichamen (ook 
wel antistoffen of afweerstoffen genoemd) zijn, net als enzymen, grote 
eiwitmolekulen. Ieder mens of dier heeft antilichamen in zijn bloed, die 
als taak hebben om ervoor te zorgen dat lichaamsvreemde stoffen 
onschadelijk gemaakt worden. Dit gebeurt door deze stoffen te binden en 
af te voeren. Men kan zo'n proces bewust opwekken door een proefdier, 
meestal een muis , in te spui ten ( immuniseren) met een 
lichaamsvreemde stof (antigeen). Als men nu dit antigeen zodanig kiest 
dat het precies past in het actieve centrum van een enzym, dan zal de 
antigeenbindingsplaats van het antilichaam opgewekt tegen dit molekuul, 
op zijn beurt weer veel moeten lijken op het actieve centrum van het 
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overeenkomstige enzym. Op deze manier kan men dus een katalytisch 
antilichaam maken. Alvorens hier dieper op in te gaan, zullen eerst de 
verschillende methoden om antilichamen te maken nader uitgelegd 
worden omdat zij een belangrijke rol hebben gespeeld in het tot stand 
komen van dit proefschrift. 
Ant ilichaam t echnologie 
Zoals al eerder genoemd, kunnen antilichamen opgewekt worden in 
muizen door immunisatie met een antigeen. Na immunisatie is het 
essentieel om de lichaamscellen van de muis die de antilichamen 
produceren in handen te krijgen en wel op een zodanige manier dat ze 
buiten de muis (in vitro) verder kunnen groeien. Meestal worden 
hiervoor de miltcellen uit de muis geïsoleerd. De milt is een orgaan dat 
rijk is aan antilichaamproducerende cellen. Deze miltcellen kunnen 
echter niet zomaar verder groeien in bv. een reageerbuis. Onderzoekers 
uit Engeland bedachten in 1975 een oplossing voor dit probleem. Zij 
fuseerden de miltcellen met myelomacellen. Myelomacellen zijn 
kankercellen d.w.z. cellen die zich oneindig blijven delen en dus het 
vermogen hebben om in vitro te groeien. In de gefuseerde cel, de 
hybridomacel, wordt het antilichaam producerende vermogen van de 
miltcel gecombineerd met het vermogen om in vitro te groeien van de 
myelomacel, waardoor er een klein antilichaamfabriekje gevormd wordt. 
Elke afzonderlijke hybridomacel produceert een specifiek (monoklonaal) 
antilichaam. De ontwikkeling van deze hybridomatechniek betekende een 
belangrijke wetenschappelijke doorbraak waarvoor de uitvinders zelfs de 
Nobel prijs ontvingen. In hoofdstuk 2 is beschreven hoe we met behulp 
van deze techniek antilichamen hebben gemaakt. 
Hoe mooi bovenstaande techniek ook is, er kleven toch nadelen aan. 
Zo moet de eerste stap in het antilichaamgeneratie proces toch door een 
proefdier, de muis, gedaan worden. Bovendien is de uiteindelijke 
antilichaamproducent, de hybridomacel, nog steeds van dierlijke origine 
en daardoor veel lastiger te kweken en genetisch te manipuleren dan 
bijvoorbeeld een bacteriële cel. Genetische manipulatie (d.w.z. het 
aanbrengen van veranderingen in het erfelijk materiaal dat codeert voor 
een eiwit) is met name van belang als men de eigenschappen van een 
antilichaam wil verbeteren. 
De laatste jaren is hard gewerkt aan een methode om antilichamen 
volledig in vitro te maken m.b.v. een bacterieel systeem. In deze 
benadering wordt het immuunsysteem als het ware nagebouwd in een 
reageerbuis. Het systeem maakt gebruik van bacteriofagen (virussen die 
bacteriën als gastheer gebruiken) en stukjes erfelijk materiaal (DNA), die 
de genetische code bevatten om anti l ichamen te produceren . 
Bacteriofagen zijn niets anders dan een stukje DNA met een eiwitmantel 
eromheen. Wanneer antilichaam DNA op de juiste plaats in het 
genetische materiaal van de bacteriofaag wordt gebracht, ontstaan er fagen 
met antilichamen op hun oppervlak. 
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De volgende stap is dan om in elke bacteriofaag een verschillend stukje 
antilichaam te zetten. Zo ontstaat er een grote verzameling fagen met 
allemaal een ander antilichaam op hun oppervlak, een zogenaamde 
antilichaam bibliotheek. Uit deze bibliotheek kunnen vervolgens die 
antilichamen geselecteerd worden die binden aan een bepaald antigeen. 
Dit gebeurt door het antigeen te immobiliseren op een oppervlak 
(bijvoorbeeld de wand van een plastic buisje) en de faag-antilichamen hier 
aan toe te voegen. Sommige antilichamen kunnen het antigeen binden 
en blijven dan ook aan het oppervlak plakken. De niet bindende fagen 
worden weggespoeld. Het is hierbij belangrijk om te bedenken dat uit één 
bibliotheek antilichamen tegen verschillende antigenen geselecteerd 
kunnen worden. 
Een geheel nieuwe toepassing van deze techniek is beschreven in 
hoofdstuk 3. Wij hebben een faag-antilichaam bibliotheek (gekregen van 
één van de grondleggers van deze techniek, Dr. Greg Winter uit 
Cambridge, Engeland) gebruikt om antilichamen te selecteren tegen een 
instabiel antigeen, gereduceerd flavine (zie figuur IA). Dit gereduceerde 
flavine is zeer gevoelig voor zuurstof, onder invloed hiervan oxideert het 
zeer snel. Het is duidelijk dat tegen dit molekuul nooit antilichamen 
gemaakt hadden kunnen worden via muis immunisatie: het is immers 
onmogelijk om een muis in een zuurstofvrij hokje te plaatsen. Fagen zijn 
echter niet afhankelijk van zuurstof en daarom kan een faag-antilichaam 
bibliotheek prima gebruikt worden om antilichamen te maken tegen 
gereduceerd flavine. Wij hebben het hele selectieproces simpelweg onder 
zuurstofvrije (anaerobe) condities uitgevoerd en op deze manier 
antilichamen verkregen die zeer specifiek binden aan gereduceerd flavine. 
Katalytische antilichamen met redox eigenschappen 
Wij hebben bovenstaande technieken gebruikt om een katalytisch 
antilichaam te bouwen dat redox reakties uit kan voeren. Een redox 
reaktie is een reaktie waarbij electronen overgedragen worden: als de 
electronen worden onttrokken aan een verbinding spreken we over 
oxidatie, als de electronen worden toegevoegd over reductie. Redox-
enzymen maken voor dit soort reakties gebruik van een extra redox-
actieve groep. Een bepaalde klasse redoxenzymen, de flavoenzymen, 
gebruikt daarvoor flavine. Ons doel was om zo'n flavoenzym na te 
bouwen en wel zodanig het een oxidatie reaktie uit kan voeren. 
Als een substraat geoxideerd wordt, worden er electronen aan 
onttrokken. Het zal duidelijk zijn dat deze electronen ergens naar toe 
moeten. Flavine is erg geschikt als electronen acceptor. Het flavine 
molekuul wordt daarbij wel zelf gereduceerd en zal dus vervolgens weer 
geoxideerd (ofwel gerecycled) moeten worden om opnieuw betrokken te 
kunnen worden bij substraatoxidatie. Een zeer geschikt molekuul om de 
electronen van flavine over te nemen is zuurstof (waarbij 
waterstofperoxide gevormd wordt). De strukturen van geoxideerd en 
gereduceerd flavine zijn weergegeven in figuur IA. 
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B: 
geoxideerd flavine 
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C: 
antilichaam + geoxideerd flavine antilichaam + gereduceerd flavine 
Figuur 1 
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Samenvatting 
De antilichamen die dit proces moeten nabootsen, moeten dus in staat 
zijn om flavine te binden en vervolgens om dit flavine te reduceren, 
waarbij dan een substraat molekuul geoxideerd wordt. De drijvende 
kracht achter deze reaktie moet dan zijn dat het gereduceerde flavine beter 
in de antigeenbindingsplaats past dan geoxideerd flavine (gereduceerd en 
geoxideerd flavine hebben verschillende conformaties). Anderzijds moet 
het ook weer niet te goed passen want het flavine moet ook weer opnieuw 
geoxideerd kunnen worden. Bovendien moet er in de antigeen-
bindingsplaats naast ruimte om het flavine te binden, ook ruimte zijn om 
het substraat te binden en wel zodanig dat het dicht bij het flavine komt te 
zitten zodat de electronen gemakkelijk overgedragen kunnen worden. 
Om aan al deze voorwaarden te kunnen voldoen, hebben we 
antilichamen opgewekt tegen het antigeen dat is weergegeven in figuur 
IB. Dit antigeen lijkt op gereduceerd flavine, maar is in tegenstelling tot 
echt gereduceerd flavine, niet gevoelig voor zuurstof. Dit komt door de 
stabiliserende werking van de benzoyl groep. Een antilichaam opgewekt 
tegen het gebogen gereduceerd flavine antigeen, zal een antigeen-
bindingsplaats hebben waar het vlakke geoxideerde flavine veel minder 
goed in past (zie figuur IC). Het vlakke geoxideerde flavine zal zich dus 
graag willen buigen, waarvoor het natuurlijk wel electronen nodig heeft, 
die geleverd moeten worden door een substraat. De extra benzoylgroep die 
aan het flavine-antigeen gezet is, heeft niet alleen een stabiliserende 
invloed, maar creëert ook een holte in de antigeen-bindingsplaats die 
ruimte biedt aan het substraat (zie figuur IC). Bovendien zal de 
benzoylgroep ook een dusdanige eiwitomgeving moeten creëren dat het 
gebogen flavine ook weer gemakkelijk zal moeten kunnen reoxideren tot 
de vlakke structuur. In hoofdstuk 2 is beschreven hoe dit veelzijdige 
antigeen gesynthetiseerd is en hoe antilichamen hier tegen zijn opgewekt. 
Naderhand is bestudeerd hoe deze antilichamen binden aan gereduceerd 
en geoxideerd flavine. 
In hoofdstuk 5 staat beschreven hoe we het katalyse proces bestudeerd 
hebben. Het blijkt dat een van de antilichamen, opgewekt tegen het 
hierboven beschreven antigeen, het flavinereoxidatie proces meer dan 10 
keer versnelt. Vergelijkbare enzymen versnellen deze reaktie 100-1000 
keer. De reductie van geoxideerd flavine kan echter niet in de 
antigeenbindingsplaats plaatsvinden, waardoor de katalytische cirkel dus 
nog niet rond is. Wat dat betreft kunnen we dus stellen dat het gelukt is 
om een antilichaam op te wekken dat als het ware voor de helft 
katalytisch actief is. 
De moleculaire basis van de flavine binding door antilichamen 
Naast het ontwikkelen van een redox actief antilichaam, hebben we 
ook onderzocht hoe nu precies geoxideerd en gereduceerd flavine op 
moleculair niveau gebonden worden in de antigeenbindingsplaats. 
Anders gezegd: waarom bindt het ene antilichaam beter aan gereduceerd 
flavine, het andere antilichaam aan geoxideerd flavine en bindt weer een 
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ander antilichaam beide redoxtoestanden even goed. Het verschil in 
binding tussen de verschillende flavine redoxtoestanden wordt uitgedrukt 
in de redoxpotentiaal. Deze redoxpotentiaal is bepaald voor twee 
antilichamen, die beide verkregen zijn uit een faag-antilichaam 
bibliotheek. Deze antilichamen zijn vervolgens uitgebreid bestudeerd 
voor wat betreft binding aan verschillende flavines, onder andere met 
behulp van fluorescentie spectroscopie. Daarnaast is van deze 
antilichamen de DNA sequentie (genetische code) bepaald en op basis 
hiervan zijn 3-dimensionale modellen van het antilichaam gebouwd (in 
nauwe samenwerking met Dr. Annemarie Honnegger uit de groep van 
Prof. Andreas Plückthun (Universität Zürich). Deze modellen zijn 
vergeleken met de experimentele gegevens en een en ander blijkt goed 
met elkaar te kloppen. Dit werk staat uitgebreid beschreven in hoofdstuk 
4. 
Tot slot wordt het onderzoek in een bredere context geplaatst en worden 
de (on)mogelijkheden van katalytische antilichamen bediscussieerd 
(hoofdstuk 6). 
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